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Podocytes are highly differentiated glomerular epithelial cells that play an essential role in the 
establishment of the glomerular filtration barrier, a structural apparatus that selectively restricts 
the filtration of different macromolecules in the blood stream on the basis of their sizes, shape 
and charge.  Podocyte dysfunction, one of the major causes of proteinuria, is of pathogenetic and 
prognostic significance in human glomerular disease.   My study is focused on the investigation 
of novel pathways leading to podocyte dysfunction and proteinuria. 
In the first part, immunoblotting and quantitative reverse transcriptase PCR (RT-PCR) 
were used to demonstrate that LIM and senescent cell antigen-like domains 1 (PINCH1) is 
induced and undergoes nuclear translocation in podocytes after transforming growth factor, beta 
1 (TGF-β1) treatment.  Bioinformatics analysis revealed the putative nuclear export 
signal/nuclear localization signal (NES/NLS) at the PINCH1 C-terminus which is required for its 
nuclear translocation.  Immunoprecipitation and GST pull-down assay identified the interaction 
between PINCH1 and Wilms tumor 1 (WT1) which led to suppression of the WT1-mediated 
podocalyxin gene expression.  In vivo, PINCH1 also underwent nuclear translocation and 
interacted with WT1 after TGF-β1 stimulation.  Our data identifies nuclear transcription factor 
WT1 as a novel binding partner for PINCH1, and provides novel insight into the mechanism of 
podocyte dysfunction under pathological conditions.    
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In the second part, RT-PCR results revealed that treatment with TGF-β1 induced gene 
expression of several wingless-type MMTV integration site family members (Wnts), 
predominantly Wnt1, and activated β-catenin in mouse podocytes.  Wnt antagonist Dickkopf-1 
(DKK1) blocked TGF-β1-induced β-catenin activation and preserved nephrin expression.  In 
vivo, ectopic expression of constitutively active TGF-β1 induced Wnt1 expression, activated 
glomerular β-catenin, upregulated its downstream target genes, and led to podocyte injury and 
proteinuria.  Consistently, concomitant expression of DKK1 gene abolished β-catenin activation 
in mouse glomeruli, inhibited TGF-β1-triggered Wnt/β-catenin target genes, and ameliorated 
proteinuria.  These results establish a role for Wnt/β-catenin signaling in the pathogenesis of 
podocyte injury and also suggest that this signaling pathway could be exploited as a therapeutic 
target for the treatment of proteinuric kidney diseases. 
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1.0  INTRODUCTION 
1.1 GLOMERULAR FILTRATION BARRIER AND PROTEINURIA 
As the vital component of urinary system, the kidneys regulate the balance of essential chemicals 
in the blood, and removes waste products and excess water from the body in the form of urine.  
The nephron is the basic functional unit of the kidney and plays an essential role in receiving and 
filtering all of the body’s blood.  The human kidney is made up of millions of nephrons.  
Nephrons are composed of 3 parts: the glomerulus, the Bowman's capsule, and the tubule, which 
are all essential in the filtration, re-absorption, and excretion processes. 
1.1.1 Glomerulus overview and function 
The glomerulus resembles a tiny ball-shaped structure made up of a twisted mass of capillaries 
and is surrounded by the Bowman's capsule (Figure 1A).  The glomerulus is semi-permeable, 
sieving the blood plasma and yielding a filtrate as urine through ultrafiltration, excluding 
albumin (68,000 mol wt) and larger serum proteins [1].  A large volume of ultrafiltrate is 
produced by the glomerulus into the capsule. As this liquid traverses the proximal convoluted 
tubule, most of its water and salt are reabsorbed.  Glomerular filtration rate, defined by the flow 
rate of filtered fluid through the kidney, is usually used to evaluate overall renal function.   
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The glomerulus comprises four resident cell types.  Mesangial cells, endothelial cells and 
podocytes are within the glomerular tuft (Figure 1B), whereas parietal epithelial cells (PECs) 
comprise the extra-glomerular tuft [2-3].  They are supported by the glomerular basement 
membrane (GBM).  Although those cells have different functions under physiological conditions, 
they are dependent on each other during glomerular development and for carrying out normal 
kidney function, as demonstrated in human genetic glomerular disease and experimental studies 
with cell-specific gene manipulations [4].  Cytokine cross-talk between cells is essential to 
maintain the anatomic structure and function of the glomerulus under both physiological and 
pathological conditions. 
 
 
Figure 1.  Structure of nephron and glomerulus.  A, Each human kidney contains about 1 
million nephrons, which are each composed of a glomerulus, a distal and proximal convoluted 
tubule and a microvascular system.  B, The glomerulus contains a fenestrated endothelium, the 
GBM, and podocytes.  Figure modified from reference [5]. 
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1.1.2 Filtration barrier structure and function 
The glomerular filtration barrier, as a delicate structure apparatus, is composed of three different 
layers: the fenestrated endothelium, GBM, and the epithelial podocyte layer (Figure 2A, B) [1, 5-
8].  It prevents the movement of large plasma-borne molecules from the capillary lumen to the 
space encompassed by the Bowman capsule; however, transglomerular pressure enables water 
and small molecular solutes to be filtered through this structure [5].  For the past three decades, 
with the advancement of tracer experiments, electron microscopes and various animal models, 
great progress has been made in the recognition of the structure, function and mechanism of the 
filtration barrier.  However, the location and nature of the filtering layers and the exact 
mechanisms of filtration have been a matter of debate [9-10].   
1.1.2.1 Glomerular endothelial cells (GECs) 
Glomerular endothelial cells (GECs) are highly specialized fenestrated cells, which 
constitute 20-50% of the glomerular capillary surface area [2, 10], allowing a higher rate of 
water and small solute exchange, restricting the permeability of macromolecules [11].  In the 
1970s, tracer experiments revealed the characterization of the fenestration structure of 
endothelial cells as numerous, circular, 50-100 nm diameter units (Figure 2C) [12-14].  These 
features allows the GEC barrier to be freely permeable to substances of small molecular 
dimensions, such as albumin (~7 nm) [11] and ferritin (~11 nm) [14]; as a result, GECs were not 
originally considered as a formal part of the glomerular filtration barrier [9].   
Although Ichimura et al. have demonstrated that only about 2% of endothelial cells form 
diaphragmed fenestrae [15], the endothelial cell fenestrae in the glomerular barrier are not just 
empty holes.  The GECs are covered by a negatively charged hydrated structure known as the 
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endothelial cell surface layer (ESL), which is composed of glycocalyx that may prevent the 
passage of albumin and other plasma proteins [7, 10-11, 16].  Electron microscopy and confocal 
microscopy of conditionally immortalized glomerular endothelial cells revealed a 200-nm thick 
glycocalyx over the plasma membrane [17], while another study showed the thickness of this 
surface layer as thick as 500 nm in animal models [18].  Previous studies have shown that the 
endothelial cell layer is important for glomerular size and charge selectivity.  In a murine study, 
treatment with glycocalyx-degrading enzymes such as hyaluronidase, heparinase, or 
chondroitinase, resulted in significantly increased urinary albumin excretion [19].  Furthermore, 
a recent study has shown that oxidative stress causes glomerular ESL deterioration by increasing 
heparanase levels, resulting in exacerbation of glomerular permselectivity and development of 
albuminuria [20]. 
The essential role of vascular endothelial growth factor (VEGF) in maintaining the GECs 
filtration function has been demonstrated by several studies.  A brief report from The New 
England Journal of Medicine has illustrated that anti-VEGF antibody treatment in patients can 
induce GEC defects associated with proteinuria, which is supported by podocyte specific 
inactivation of VEGF in mouse model [21-22].  Additionally, podocyte-specific overexpression 
of the VEGF-164 isoform led to collapsing glomerulopathy in HIV-associated nephropathy and 
diabetic nephropathy [22-23].  These results suggest that GECs are critical in maintaining the 
integrity and function of glomerular filtration barrier. 
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Figure 2.  Glomerular filtration barrier.  A, Glomerular filtration barrier is composed of three 
layers: an inner fenestrated endothelium with glycocalyx, the glomerular basement membrane 
(GBM), and podocytes with foot processes.  B, Transmission electron micrograph of a transverse 
section through the wall of a normal rat glomerular capillary.  C, Scanning electron micrograph 
of glomerular endothelial cell fenestration in a mouse glomerular capillary.  D, Scanning electron 
micrograph of the interdigitating foot processes encompassing capillary loops.  P, podocyte cell 
body;  FP, foot process;  SD, slit diaphragm;  GBM, glomerular basement membrane; F, 
endothelial fenestration.  Figure modified from reference [10-11, 24]. 
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1.1.2.2 Glomerular basement membrane 
The glomerular basement membrane (GBM) is an acellular matrix and fundamental structure of 
the glomerular capillary.  Glomerular endothelial cells and podocytes anchor to each side of 
GBM.  The GBM is a 300-350 nm thick gel-like structure that arises from the fusion of two 
basement membranes during the development: one is synthesized by the glomerular 
endothelium, and the other is from the glomerular epithelium during the early stages’ 
development [1].  It is mainly composed of the type IV collagen, laminin, entactin/nidogen and 
the heparin sulfate proteoglycans (HSPGs) [25]. 
The GBM had been considered to play a central role as a size- and charge-selective 
filtration barrier.  However, recent studies have presented challenges to this concept.  HSPGs are 
believed to provide anionic charge to the GBM and contribute to the charge selectivity.  
Decreased expression of HSPGs has been shown in the patients with diabetic kidney disease by 
immunostaining [26-28] and in an animal model of active Heymann nephritis [29].  Intravenous 
injection of monoclonal antibody against GBM heparin sulfate has been reported to induce a 
dose-dependent, transient and selective proteinuria that was maximal immediately after the 
injection [30].  Also, knock-in mice lacking the HS chains at the N-terminal domain I of perlecan 
(a major component of HSPG in the glomerular basement membrane) were highly susceptible to 
protein overload [31].  To question this concept, Dr. Miner’s group revealed that agrin- or 
perlecan-heparan sulfate- deficient and conditional knockout mice do not alter glomerular 
permselectivity, even though agrin contributes significantly to the anionic charge to the GBM 
[32-33].  Furthermore, other studies questioned the significance of the charge selectivity of 
glomerular barrier using charged and uncharged macromolecules [34-35]. 
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Type IV collagen is across-linked network of three sets of triple-helical molecules that 
self associate with their C-terminal domains and middle triple-helical regions [36].  The network 
of type IV collagen mainly functions as a basic basement membrane scaffold with laminin to the 
glomerular capillary wall, although it makes little contribution to filtration selectivity [9, 36].  
The mutations in type IV collagen genes, such as COL4A3, COL4A4 or COL4A5, lead to the 
autosomal recessive Alport syndrome characterized by hematuria, proteinuria (less than 1 to 2 g 
of protein excreted per day), progressive renal failure, and sensorineural deafness [37].  
Laminins are heterotrimeric proteins, which form a network with type IV collagen in the 
GBM.  The main laminin in the mature GBM is laminin-521, which is composed by α5, β2 and 
γ1 chains [10].  Laminin-521 has been demonstrated to play as essential role in maintaining the 
glomerular ultrafiltration function by laminin-β2 deficient mice which develop massive 
proteinuria [38].  In human patients with Pierson syndrome (a rare congenital nephrotic 
syndrome), mutations in gene LAMB2 have been identified [39].  Jarad G. et al have shown that 
GBM permeability to ferritin was dramatically elevated in Lamb2-/- mice by electron-dense 
tracer experiments, even before the appearance of foot process effacement, which demonstrates 
the significance of GBM in the glomerular barrier being a different perspective [40]. 
1.1.2.3 Podocyte foot process 
Podocytes are highly differentiated glomerular visceral epithelial cells, which are characterized 
by their sophisticated foot processes described as the interdigitation structure between the 
neighboring cells (Figure 2D).  The foot processes are anchored firmly to the underlying GBM 
by transmembrane cell receptors and proteins, such as integrins and tetraspanins [9].  The 
podocyte foot processes form 30-45 nm-wide filtration slits that are connected through 
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specialized adhesion complexes known as the slit diaphragm [14].  This porous substructure of 
the glomerular slit diaphragm was revealed by Rodewald et al. with transmission electron 
microscopy in 1974, which suggested the principal role of the slit diaphragm in the glomerular 
filtration selection [14].  In the past decade, the role of the podocyte in the filtration process has 
become the focus of nephrology research, and increasingly convincing findings have expanded 
the understanding of biology and pathology of the glomerular filtration barrier.  The structure 
features of podocyte will be addressed in detail in Chapter 1.2.  
1.1.3 Defective filtration and proteinuria 
From the clinical standpoint, glomerular diseases are generally classified into two categories 
based on the magnitude of proteinuria and the presence of red blood cells: nephritic syndrome 
and nephrotic syndrome [2].  Nephritic syndrome is characterized by diffuse inflammatory 
changes in the glomeruli; however, nephrotic syndrome is characterized by the defects in 
glomerular capillary wall permeability, with heavy proteinuria [41].  Proteinuria, the clinical 
manifestation of structural and functional defects in glomerular filtration barrier, often occurs in 
the early stages of many forms of primary glomerular disease [42].  In the most common 
proteinuric kidney diseases, including focal segmental glomerulosclerosis, minimal change 
disease, membranous nephropathy (including lupus), diabetic nephropathy, and IgA 
nephropathy, proteinuria is closely related to a defective filtration process.  
The maintenance of normal filtration function is based on the integrity of all three layers 
of the glomerular capillary wall, even though studies from the last decade demonstrate the 
pivotal role of podocyte foot processes in the filtering process.  Advances in understanding the 
molecular structure of the filtration barrier will allow for the identification of genetic defects as 
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the cause of numerous glomerular diseases.  Molecular profiling, transgenic mice and gene 
therapy will reveal novel therapeutic strategies for the treatment of proteinuric glomerular 
diseases in the future. 
1.2 PODOCYTES 
1.2.1 Podocyte structure 
Podocytes are highly differentiated epithelial cells which are developmentally derived from the 
metanephric mesenchyme through mesenchymal to epithelial transdifferentiation (MET) [43].  
The interdigitating foot processes of podocytes are the unique aspect of glomerular development, 
and are the fundamental structure that maintains filtration function and prevents glomerular 
disease.  On the basal side, the foot processes are anchored firmly to the GBM through 
transmembrane proteins and receptors and are arranged in a highly organized way to envelope 
the capillary wall.  On the lateral side, foot processes of two adjacent podocytes are connected 
through specialized adhesion complexes termed the glomerular slit diaphragm.  Podocalyxin, the 
main molecular component on the apical side, is responsible for the negative charge to maintain 
the normal podocyte architecture [44] .   
Although the three domains are functionally independent with specialized protein 
expression, the cytoskeleton is connected to all three plasma membrane domains and brings 
signals together from the extracellular matrix, as shown in Figure 3.  In foot processes, the 
cytoskeleton is highly organized in actin-based bundles that run parallel to the longitudinal axis 
of foot processes [10].  Foot processes are thought to modulate the permeability of the filtration 
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barrier through changes in foot process morphology.  Interference with any of the three foot 
process domains changes the actin cytoskeleton from parallel contractile bundles into a dense 
network, which leads to foot process effacement [45].  
 
Figure 3.  Podocyte foot process.  At basal domain, podocyte foot processes are attached to the 
GBM through integrins and dystroglycans; at lateral domain, slit diaphragm complex cover the 
space between adjacent foot processes and connects them together; at apical domain, negatively 
charged podocalyxin is the main component.  The actin cytoskeleton interconnects three plasma 
membrane domains together through adaptor proteins. Figure modified from reference [10]. 
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1.2.2 Signaling in podocytes 
1.2.2.1 Signaling at the slit diaphragm 
The slit diaphragm complex is composed of several plasma-membrane proteins including 
nephrin, podocin, NEPH1-3, Fat1, VE-cadherin and P-cadherin [9].  Nephrin, podocin, NEPH1, 
and Fat1 are essential for the normal glomerular filtration function.  Nephrin was the first slit 
diaphragm protein cloned by the Tryggvason group in 1998 [46].  Their report was the first to 
reveal that nephrin-coding gene (NPHS1) is mutated in congenital nephritic syndrome of the 
Finnish type, and also provided fundamental insight into the molecular mechanisms of 
glomerular filtration.  Nephrin is a transmembrane protein that belongs to the immunoglobulin 
superfamily.  It contains eight extracellular immunoglobulin domains which interact with the 
other immunoglobulin domains from adjacent foot process to form a zipper-like structure.  The 
cytoplasmic region of nephrin has a series of conserved tyrosine-based motifs which upon 
phosphorylation can serve as binding sites for SH2 domain containing proteins, such as the 
adaptor protein Nck [47-49].  Like other transmembrane receptors, nephrin can signal via second 
messengers to the cytoskeleton through the binding of intracellular adaptor proteins.  Nephrin 
knockout mice are born without typical slit diaphragms and have severe proteinuria [50].  
Furthermore, the reduction and pattern change of nephrin expression has been observed in 
several human nephropathies and animal disease models, which suggests that nephrin is essential 
for normal glomerular function. 
Several other components of the slit diaphragm have been recently identified, allowing us 
to better understand this delicate complex.  In 2000, Boute, N. et al identified the causative gene 
for the congenital nephritic syndrome type 2, NPHS2, using positional cloning [51].  The NPSH2 
gene encodes a membrane protein named podocin, which is localized at the slit diaphragm region 
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and mediates nephron signaling through interaction with the cytoplasmic tail of nephrin [52].  
Nphs2-/- mice displayed rearrangement of foot processes and lack of the slit diaphragm, 
associated with proteinuria during the antenatal period, and died a few days after birth from renal 
failure caused by massive mesangial sclerosis [53].   
CD2AP, an adaptor protein, binds directly with nephrin and podocin, and serves as an 
anchor between the slit diaphragm and actin cytoskeleton [54-55].  CD2AP knockout mice 
exhibited defects in foot processes and died at 6 to 7 weeks of age due to massive proteinuria and 
renal failure [56].  Similarly, the adaptor protein Nck has also been shown to interact with the 
intracellular tail of nephrin upon its phosphorylation and link it to the actin cytoskeleton in the 
podocytes [47, 49].  Mice missing Nck proteins in podocytes develop massive proteinuria and 
foot process effacement [47].  Taken together, adaptor proteins linking the slit diaphragm to the 
cytoskeleton are crucial to mediate actin polymerization and the cytoskeleton reorganization in 
maintaining foot process structure and function. 
1.2.2.2 Signaling between GBM and foot processes 
Podocytes attach to the underlying GBM through two major cell adhesion complexes: 
integrins and dystroglycans [57].  Integrins are αβ heterodimeric proteins that are indirectly 
linked to the actin cytoskeleton through integrin associated proteins.  In podocytes, 
α3β1 integrin is the most abundant isoform.  Mice with a homozygous mutation of α3 integrin 
exhibited defects in kidney development, including decreased extent of branching of glomerular 
capillary loops, disorganized glomerular basement membrane and failure to form mature foot 
processes [58].  Podocyte specific deletion of β1 integrin in mice leads to massive proteinuria, 
foot process effacement and podocyte detachment from GBM [59-60].   Beta1 integrin binds to  
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laminins, an important component of GBM.  The lack of β1 integrin results in the failure to form 
heterotrimeric laminins due to the absence of α1 and α5 laminin chain recruitment into the 
assembled basement membrane [59].  The disruption of the interaction between integrins and 
laminins may weaken the interaction between GBM and podocytes and induce foot process loss 
and podocyte detachment.  The role of dystroglycans in foot process is still poorly understood.  
A recent paper has shown that the antibody against α-dystroglycan on podocytes induces 
intracellular calcium signaling, which leads to altered cytoskeleton architecture  and  foot process 
effacement [61].  
Integrin linked kinase (ILK) has also been demonstrated to play an important role in the 
glomerular filtration barrier.  Two independent studies reported progressive proteinuric renal 
disease in mice with podocyte-specific deletion of ILK.  Although one study focused on the 
thickening of the GBM followed by the abnormal distribution of α3 integrin, the other 
emphasized the interaction between ILK, nephrin and α-actinin-4, and the redistribution of 
nephrin caused by the disruption of this complex [62-63].  
1.2.2.3 Signaling at the apical surface 
Podocalyxin is the main component coating the apical membrane of foot processes and 
the major sialoprotein in the glycocalyx of glomerular podocytes [44].  This membrane protein is 
responsible for the negative charge of the foot process apical domain and maintaining open 
urinary space.  Podocalyxin knockout mice fail to form foot processes and slit diaphragms and 
instead exhibit cell-cell junctional complexes (tight and adherens junctions) and died of the renal 
failure.  In addition, the corresponding reduction in permeable, glomerular filtration surface area 
presumably leads to the observed block in urine production [64].  This suggests that podocalyxin 
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is crucial for the development of the normal podocyte foot process structure and filtration 
function.  It has also been shown that podocalyxin is linked to actin cytoskeleton through ezrin, 
Na+/H+-exchanger and NHERF1 in podocytes, and induce actin reorganization [65-67].  The 
disruption of this complex has been reported in some animal models with foot process 
effacement and proteinuria. 
1.2.3 Transcription regulator WT1 
The delicate morphology and function of podocytes are ultimately controlled by their unique 
nuclear transcriptional program.  In this regard, WT1, the product of Wilms tumor suppressor 
gene, is the key transcription factor that plays a fundamental role in controlling the expression of 
major podocyte-specific genes in the adult kidney [68-73].  During kidney development, WT1 
expression is first detected in the uncondensed metanephric blastema, and dramatically increases 
in condensed mesenchyme during the mesenchymal to epithelial transdifferentiation [74].  It has 
been shown that WT1 expression is strongly associated with differentiation of metanephric 
blastemal cells into epithelial cells [75].  In adult kidney, WT1 expression is exclusively 
restricted to glomerular podocytes, and is not present in other terminally differentiated cells, 
including epithelial cells.  Based on these findings, WT1 is often utilized as a molecular marker 
for evaluating podocyte number and density under different circumstances [76].  In humans, 
WT1 mutations are associated with several glomerulopathies, including Wilms tumor, Deny-
Drash syndrome, Frasier syndrome and diffuse mesagnial sclerosis.  
As a transcription factor, WT1 contains four zinc-finger DNA-binding motifs at the 
carboxyl-terminus and a proline/glutamine-rich domain at the amino-terminus.  WT1 has 24 
transcript variants due to the different start sites, alternative RNA splicing at two coding exons 
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and RNA editing, and it has been shown that this process is tissue-specific and developmentally 
regulated [77].  Three alternative translation start sites have been identified: major ATG site, 
CTG site at 204 bp upstream of the major site; and the second in-frame ATG at 381 bp [74].  
additionally, two alternatively spliced exons are also known: one effects exon 5, which encodes 
17 amino acids that are included or omitted between the Pro/Glu-rich N-terminus and the Zn 
finger domain; the other effects exon 9 by insertion or exclusion of three amino acids KTS 
(lysine-threonine-serine) between the third and fourth zinc fingers [69, 74].  Also, an RNA 
editing site has been shown to lead to the replacement of an amino acid in exon 6 in the 
transcription of human and rat WT1 gene [77].   
Among the 24 isoforms, we know very little about isoforms produced from alternative 
translation start sites.  WT1 isoforms with exon 5 slow cell growth to a lesser extent than the 
isoform without exon 5, and result in altered cellular morphology and initiate the mesenchyme-
to-epithelial transition during metanephric development [78].  The mouse model carrying the 
deletion of exon 5 showed that exon 5 is not a major modifier of WT1 function [79].  The ratio 
of exon 5 spliced isoforms differs among cell types, species and developmental stages, whereas 
the ratio between WT1 (-KTS) and WT1 (+ KTS) is constant in all cell types.  Mutations leading 
to the ratio change between WT1 (-KTS) and WT1 (+KTS) can cause Fransier syndrome in 
humans which is presented at birth with male pseudohermaphroditism, streak gonads and 
progressive glomerulonephropathy [69].  WT1 (-KTS) and WT1 (+KTS) have been shown to 
have different nuclear localization: WT1 (-KTS) isoforms re diffuse in the nuclei as transcription 
factors, whereas WT1 (+KTS) isoforms colocalize with splicing factors [80].  WT1 (-KTS) 
isoforms bind to DNA and regulate transcription of the target genes; however, WT1 (+KTS) 
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isoforms show a higher affinity for RNA as compared to DNA, and play a role in RNA splicing 
during the post-transcriptional modification [81].   
WT1 can either activate or repress gene transcription, depending on cell-context and 
different target genes.  Based on binding site selection and transient transfection, about 20 
different genes have been identified as the targets of WT1, including C-myc, TGF-β1, IGF2, 
EGF1, EGFR, Bcl-2.  Results show that WT1 affects the promoter activity of all these target 
genes [82].  Besides, WT1 enhances the expression of E-cadherin in NIH 3T3 fibroblasts by 
activation of the murine E-cadherin promoter through a conserved GC-rich sequence similar to 
an EGR-1 binding site and through a CAAT box sequence [83].  During kidney development, 
WT1 can target podocalyxin, nephrin and amphiregulin gene expression by binding to their 
promoters, resulting in potent transcriptional activation [70, 72, 84].  These observations support 
the role for WT1 in conferring the specific activation of a glomerular differentiation program in 
renal precursors and provide a molecular basis for some glomerulonephropathies.  Recently, a 
new WT1 transcriptional target gene, CXXC5 has been identified that negatively regulates 
Wnt/β-catenin signaling in vitro and in vivo [85]. 
1.2.4 Podocyte dysfunction and proteinuria 
In the recent decades, increasing evidence indicates that podocyte dysfunction plays a central 
role in conferring the defective glomerular filtration and onset of proteinuria.  Podocyte 
dysfunction is characterized by foot process effacement, slit diaphragm loss, and ultimately 
leading to apoptosis and cell depletion.  Proteinuria is an early pathologic feature caused by 
podocyte dysfunction in many common forms of chronic kidney diseases, such as diabetic 
nephropathy and focal segmental glomerulosclerosis.  On one hand, a large number of genetic 
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studies have revealed that mutations or deletions of some crucial genes are consequently 
associated with the development of proteinuria in both animal models and patients; on the other 
hand, the mechanism that induces podocyte dysfunction in many acquired forms of proteinuric 
kidney diseases without inherited gene changes remains ambiguous.   
As mentioned above, three domains compose the delicate filtration structure of podocyte 
foot processes: the slit diaphragm, the basal domain attached to the GBM, and the apical domain, 
which are associated with the actin cytoskeleton.  The disruption of domain integrity is a critical 
event in the development of proteinuria and nephritic syndrome.  Foot process effacement may 
result from disruption of any of these domains and rearrangement of the actin cytoskeleton.  
Advances in the understanding of the molecular structure of the podocytes have revealed the 
major role of genetic defects play in the development of podocyte dysfunction and proteinuria.  
Proteins that are associated with the slit diaphragm (for example, nephrin, podocin, α-actinin 4, 
the adaptor protein CD2AP, and trPC6), and those that anchor the foot processes to the GBM 
(for example, α3β1 integrin, α-actinin 4, vinculin, talin, and the tetraspanin, CD151), together 
with those that localize on the apical domain (for example, podocalyxin), and transcription 
factors (for example WT1 and lim homeobox transcription factor 1β), all have an important role 
in the prevention of proteinuria [5].  Mutations and deletions of those genes causing to foot 
process effacement, podocyte morphology change and proteinuria are involved in various 
podocyte-associated glomerular diseases in humans and genetic mouse models, as shown in 
Table 1. 
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Table 1.  Genes involved in podocyte associated genetic glomerular diseases. 
Disease (OMIM number) Gene Protein 
Congenital nephrotic syndrome of the Finnish type (256300) NPHS1 Nephrin 
Congenital nephrotic syndrome type 2 (604766) NPHS2 Podocin 
Familial nephrotic syndrome type 3 (610725) PLCE1 Phospholipase Cε1 
Frasier syndrome and Denys–Drash syndrome (136680 and 
194080) 
WT1 wilms’ tumor 1 
Schimke immuno-osseous dysplasia (242900) SMARCAL1 hHARP 
Nephrotic syndrome caused by mutations in CD2AP (604241) CD2AP CD2AP 
Nephrotic syndrome caused by mutations in actinin-4 (604638) ACTN4 α-Actinin-4 
Nephrotic syndrome caused by mutations in TRPC6 (603652) TRPC6 TRPC6 
Epstein and Fechtner syndrome (153640 and 153650) MYH9 NMMHC-A 
Nail–patella syndrome (161200) LMX1B LMX1B 
Table modified from reference [5]. 
However, genetic causes of podocyte dysfunction explain only a small fraction of 
proteinuric nephropathies.  Mutations are rare in most common forms of chronic kidney diseases 
such as diabetic nephropathy [86].  In this regard, the exact mechanisms causing podocyte 
dysfunction in the vast majority of acquired proteinuric kidney diseases are not yet fully 
delineated.  Li et al have proposed that epithelial-mesenchymal transition (EMT) could be a 
potential pathway leading to podocyte dysfunction and proteinuria under pathological conditions 
by investigating podocyte EMT after incubation with TGF-β1 in vitro [42].  Podocyte EMT is 
described by loss of epithelial P-cadherin, ZO-1 and podocyte-specific nephrin, and the 
acquisition of mesenchymal fibroblast-specific protein-1 (Fsp1), desmin, collagen I, fibronectin 
and transcription factor Snail1, and represents changes consistent with tubular EMT [42].  It is 
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conceivable that podocytes undergo a range of adaptive changes in response to injury, including 
hypertrophy, autophagy, dedifferentiation, EMT, detachment and apoptosis.  EMT certainly 
results in podocyte dysfunction, and ultimately leads to podocyte detachment from GBM, onset 
of proteinuria and glomerulosclerosis [43].  However, this explanation is not without 
controversy, because these cells possess sophisticated foot processes in vivo and express 
vimentin, characterizing them mesenchymal appearance at baseline.  Three major signaling 
pathways, including TGF-β1, integrin/ILK and Wnt/β-catenin signaling, are involved in 
conferring podocyte EMT, and these pathways will be discussed in detail in following chapters. 
1.3 TRANSFORMING GROWTH FACTOR-β AND PODOCYTE INJURY 
1.3.1 TGF-β structure and activation 
Transforming growth factor-beta (TGF-β), including TGF-β1, TGF-β2 and TGF-β3, is a family 
of cytokines that regulate cell proliferation, differentiation, adhesion, migration, apoptosis and 
other functions, during embryogenesis as well as in mature tissues [87].  
The three members of the TGF-β family have similar peptide structure. They are all 
encoded as large protein precursors; TGF-β1 contains 390 amino acids, TGF-β2 and TGF-β3 
each contains 412 amino acids [88].  Most types of cells secrete TGF-β in a biologically inactive 
form.  For example, TGF-β1 has an amino-terminal signal peptide of 29 amino acids that is 
required for secretion from the cell, a pro-region of the precursor from amino acid 30-278 is 
cleaved to become 25 kDa latency associated peptide (LAP), and a 112 amino acid carboxy-
terminal region that becomes the mature TGF-β molecule following its release from the pro-
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region by proteolytic cleavage with the endopeptidase furin [88-89].  The proteolysis yields two 
products that assemble into dimers.  Previous analysis has shown that TGF-β1 is secreted as a 
complex with the active TGF-β1 dimer in a noncovalent interaction with two pro-region 
polypeptides [90].  The LAP act as chaperones to facilitate the secretion of the mature TGF-β1 
and render this complex latent [91].  The cysteines in positions 223 and 225 in the pro-region are 
important for the association of LAP with TGF-β-1 by interchain disulfide bonds.  When 
cysteines are substituted by serines in positions 223 and 225 of the LAP, the TGF-β1 is secreted 
in an active form [89].  The third cysteine in position 33 is involved in binding to another protein 
called the latency binding protein (LTBP) [92].  When latent TGF-β is associated with an LTBP 
protein it is referred to as large latent TGF-β while latent TGF-β alone is referred to as small 
latent TGF-β [88].  The small latent TGF-β remains in the cell until it is bound by LTBP to form 
a Large Latent Complex which can be secreted into the extra cellular matrix [93].   
As part of the large latent complex, TGF-β is not activated to interact with its receptors, 
because LAP functions as an inhibitor owing to its noncovalent, high-affinity association with 
TGF-β [94].  Further processing is needed to release active TGF-β from the complex.  Some of 
the known activating pathways are cell or tissue specific, while some are seen in multiple cell 
types and tissues.  Since different cellular mechanisms require distinct levels of TGF-β signaling, 
the inactive complex of this cytokine gives the opportunity for proper fine-tuning of TGF-β 
signaling [94].  To activate TGF-β proteins, LAP can be removed by several ways in vitro and in 
vivo including extremes of pH, heat, chaotropic agents and substances like SDS and urea, 
proteases, thrombospondin-1(TSP-1), integrins, and reactive oxygen species (ROS).  Mild acid 
treatment (pH 4.5) is sufficient to induce TGF-β activation both in vivo and in vitro.  This 
process may be mediated by denaturing LAP, thereby disturbing the interaction between LAP 
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and TGF-β [95].  Proteases including plasmin, MMP-2 and MMP-9 have been identified in vitro 
as latent TGF-β activators, however, mice that have null mutations in the genes that encode the 
known activating proteases do not demonstrate any phenotypes consistent with TGF-
β deficiency [94, 96-97].  This may indicate redundancy among the activating enzymes in mice.  
TSP-1 can activate TGF-β1 through direct binding with LAP in vivo.  TSP-1 knockout mice 
show partial overlapping phenotype with TGF-β1 knockout animals, which supports the 
contention that TSP-1 is an activator of latent TGF-β [98].  Integrins including αvβ6 and αvβ8 
have been reported as TGF-β activators, despite different mechanisms: activation of TGF-β by 
αvβ6 depends on direct interaction with the RGD amino acid sequence present in LAP-β1 and 
LAP-β3, which plays important role in wound healing and inflammation [99]; and activation by 
αvβ8 requires the protease MT1-MMP [100].  ROS produced by irradiation in vitro and in vivo 
can disable LAP by hydroxyl radical-induced digestion and modification, which reflects 
important role of TGF-β in inflammation and apoptosis due to oxidative stress [101].  
1.3.2 TGF-β signaling pathway 
TGF-β exerts its biological activity by binding to transmembrane serine/threonine kinase 
receptors, which exist in several different homodimeric and heterodimeric isoforms [102].  There 
are three types of TGF-β receptors: I, II, and III, all of which consist of amino-terminal 
extracellular ligand binding domain, a transmembrane region and a carboxy-terminal 
serine/threonine kinase domain [87].  Both types I and II receptors have a high affinity for TGF-
β1 and low affinity for TGF-β2, while receptor type III has a high affinity for both TGF-β1 and -
β2 [103].  TGF-β1 initiates signaling by binding to the constitutively active receptor type II, 
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leading to the recruitment of receptor type I to form a hetero-oligomeric signaling complex 
[104].  In contrast, TGF-β2 binds to receptor type III, which presents the cytokine to receptor 
type II upon oligomerization of both receptor types, since receptor type II has a low affinity for 
TGF-β2 [105].  Once type II receptor is activated, it recruits and phosphorylates serine residues 
of receptor type I at its GS domain, and stimulates a ubiquitous intracellular signaling cascade 
[87, 106]. 
The canonical signaling of TGF-β is transduced by intracellular mediator Smad proteins, 
which are identified as Mad in Drosophila.  Upon activation, the type I receptor recruits and 
phosphorylates a receptor regulated Smad (R-Smad).  So far, 10 Smad proteins have been 
identified, and among which, only Smad2 and Smad3, as R-Smad, respond to signaling by the 
TGF-β subfamily.  The R-SMAD then binds to Smad4, the common Smad (CO-Smad), and 
forms a heterodimeric complex that moves into the nucleus where they interact in a cell-specific 
manner with various transcription regulators to control the transcription of many pro-fibrogenic 
genes [87, 107].  On the contrary, Smad6 and Smad7 block the phosphorylation of Smad2 and 
Smad3, thus inhibiting the TGF-β induced inflammatory response [106, 108].   
Smad4 and all R-Smad except Smad2 can bind to DNA through the minimal Smad 
binding element (SBE) which contains only four base pairs, 5’AGAC3’ [109].  R-Smad binds to 
DNA through a highly conserved β hairpin which makes specific contacts with the three bases of 
the SBE, whereas a unique 30 residue insertion in Smad2 peptide inhibits the formation of β 
hairpin, resulting in the poor binding of Smad2 to DNA [110].  In addition to the SBE, a G/C 
rich sequence has also been reported as Smad binding elements [87].   
The expression of hundreds of genes is either positively or negatively altered by TGF-β 
stimulation.  The same set of Smad complexes is required for both activation and repression of 
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targeted genes.  It is believed that the different responses to TGF-β signaling are based on the 
genetic makeup and environment of the target cell [111].  Due to the relatively low affinity 
between single copy of SBE and individual Smad proteins, Smads have to cooperate with each 
other and other DNA binding proteins to elicit specific transcriptional responses.  Some of those 
factors are universal and mediate the same response in all types of cells; however, others are cell 
type specific leading to cell type dependent response [87].  Many DNA binding proteins, 
including E-box, Jun/Fos, Runx, CREBP, E2F and homeobox, have been reported as partners of 
Smad proteins [111]. 
1.3.3  TGF-β signaling in kidney diseases  
Renal fibrosis is considered a hallmark and consequence of chronic kidney disease based on 
experimental and clinical research of the pathophysical processes leading to end-stage renal 
failure [106].  Renal fibrosis is a condition characterized by excessive accumulation and 
deposition of extracellular matrix, and results in glomerulosclerosis and tubulointerstitial fibrosis 
[112-113].  TGF-β is one of the most important mediators in this process.  Overexpression of 
TGF-β is closely related with pathological condition of renal fibrosis, although its physiological 
expression is required for normal development [101, 106-107, 111].   
The upregulation of TGF-β isoforms is found in a variety of human progressive renal 
diseases, such as diabetic nephropathy, IgA nephropathy, lupus nephritis, focal and segmental 
glomerulosclerosis and crescentic glomerulonephritis [114].  Diabetic nephropathy, for example, 
significantly elevated plasma levels of TGF-β1 are found in patients with type 2 diabetes [115], 
and higher urinary excretion of TGF-β1 is observed in patients with diabetes mellitus than in 
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normal controls, especially in patients with severe mesangial expansion [116].  In diabetic db/db 
mice, it has been shown that significantly increased TGF-β1 mRNA and protein expression by in 
situ hybridization and immunostaining in both glomerular and tubular compartments [117].  The 
upregulation of TGF-β type II receptor and activation of Smad3 in this mouse model also 
demonstrates the active signaling downstream of the TGF-β stimulus [117].  The extracellular 
matrix proteins, including biglycan, fibronectin, tenascin and collagens are all induced in 
glomeruli in response to the stimulus of elevated TGF-β [118].  
Besides diabetic mouse models, TGF-β overexpression has been described in several 
animal experimental models, including nephropathy associated with ureteral obstruction, 
puromycin aminonucleoside nephrosis, anti-Thy-1 rat model of proliferative glomerulonephritis, 
anti-GBM glomerulonephritis, and age-related nephropathy [106].  Injection of puromycin 
aminonucleoside results in focal glomerulosclerosis with proteinuria and stable overexpression 
of TGF-β1 [119].  In rats with surgical removal of renal mass, TGF-β mRNA increases from 
early stage and induces α-smooth muscle actin (α-SMA), leading to renal fibrosis [120].  Also, 
in this model, overexpression of desmin and loss of synaptopodin in podocytes are associated 
with an enhanced TGF-β mRNA expression [120].   
TGF-β induces extracellular matrix deposition by both stimulating production of the 
matrix proteins and reducing the synthesis of matrix degrading protease [121].  In vitro, TGF-β 
induces desmin, fibronectin and collagen in podocytes, glomerular mesangial cells and tubular 
epithelial cells [42, 122].  On the other hand, plasmin generation from plasminogen is regulated 
by plasminogen activators (PAs) and plasminogen activator inhibitors (PAIs) [123].  Previous 
studies showed that PA activity was markedly reduced and PAI-1 synthesis dramatically 
increased in glomeruli treated with TGF-β [123].  TGF-β signaling is a well-known inducer of 
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epithelial to mesenchymal transition (EMT), which emerges as an important pathway to generate 
fibroblasts and myofibroblasts in diseased kidney [43, 124].  TGF-β/Smad signaling can regulate 
the expression of various EMT related genes, including Snail, desmin, Fsp-1, MMP-9, 
fibronectin, collagen, α-SMA, PINCH1 and ILK in podocytes and epithelial cells [42, 125-127].  
The induction of EMT by TGF-β is mediated by induced Snail expression, which is the key 
EMT regulator [128].  It should be noted that podocytes might respond differently to TGF-β 
stimulation according to its specific concentrations.  A high concentration of TGF-β1 causes 
podocyte apoptosis [129]. 
Since TGF-β plays such an important role in the pathogenesis of glomerulosclerosis and 
tubulointerstitial fibrosis, it is a significant therapeutic target for the prevention of renal fibrosis.  
Earlier studies have shown that a natural inhibitor of TGF-β, the proteoglycan decorin, can bind 
to TGF-β and neutralize its bioactivity, which leads to suppression of glomerular matrix 
production and prevents matrix accumulation in the injured glomeruli [130].  More in vivo 
studies of TGF-β neutralizing antibodies have demonstrated that antagonism of TGF-β can 
inhibit glomerulosclerosis and tubulointerstitial fibrosis in a variety of mouse models, including 
unilateral ureteral obstruction (UUO), puromycin aminonucleoside-induced nephrosis, anti-Thy-
1 nephritis, cyclosporine-induced nephropathy and mouse model of diabetic nephropathy [131-
134].  The suppression of progressive proteinuria and renal damage is associated with decrease 
in phosphorylation of Smads in the glomeruli and tubular cells [132].  TGF-β receptor 
antagonists can also play the similar role in reducing proteinuria, PAI-1 expression, and 
phosphorylation and nuclear translocation of Smad2/3 [135].  Also, TGF-β short-interfering 
RNA has been used to suppress target genes type I collagen and PAI-1 in cultured mesangial 
cells and in UUO mouse model [136]. 
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To sustain the normal immune response by maintaining the physiological level of TGF-β, 
the downstream profibrotic Smads may be a better target in preventing progressive renal injury 
associated with TGF-β signaling.  Gene therapy with Smad7, as a natural antagonist of TGF-β 
signaling, has been shown to attenuate renal fibrosis by inhibition the Smad2/3 activation [137].  
Hepatocyte growth factor (HGF), as an antifibrotic factor, also has been reported to block Smads 
signaling by inducing Smad transcriptional corepressor Ski-related novel protein N (SnoN) 
expression [138].  
To summarize, TGF-β signaling plays a critical role in progressive renal diseases, which 
is confirmed by numerous studies in various experimental models and clinical studies.  Targeting 
TGF-β signaling as the therapeutic strategy may provide a promising remedy in the treatment of 
renal disease in humans.   
1.4 PINCH 
1.4.1 IPP complex and integrin signaling pathway 
IPP is a heterotrimeric complex, which contains integrin-linked kinase (ILK), particularly 
interesting Cys-His-rich protein (PINCH), and parvin.  It functions primarily as a signaling 
platform for integrins by connecting with the actin cytoskeleton and many diverse signaling 
pathways, and also as a regulator of gene transcription and cell-cell adhesion [139].   
The extracellular matrix (ECM) influences various intracellular signal pathways that 
regulate survival, proliferation, polarity and differentiation by binding to cell surface receptors.  
Integrins, one of the most important families of adhesion molecules, are heterodimeric 
 27 
transmembrane molecules consisting of α and β subunits [140].  Protein-kinase-C can facilitate 
the conformational change of integrins to promote the binding between integrins and their 
ligands [139].  β1 integrin is widely expressed and contributes to a large number of integrin 
heterodimers.  β1 integrin is the only β subunit expressed in the glomerular cells, where it forms 
heterodimers with different α subunits including α1, α2, α3, α5, and α8 [141].  The IPP 
complex links integrins to the actin cytoskeleton, and mediates signal transduction between the 
intracellular and extracellular compartments [142-144]. 
In this complex, ILK is the central component, and it binds to the cytoplasmic tail of β1 
integrin [145] and β3 integrin [146].  ILK was originally identified in a yeast-hybridization 
system for screening the binding partner of β1 cytoplamic tail in 1996 [145].  Subsequent studies 
have revealed the structure of ILK: three ankyrin repeats located at the amino-terminus, which 
mediate protein–protein interactions, and a putative fourth ankyrin repeat that lacks conserved 
residues; sequence homology to serine/threonine protein kinases located at the carboxy-terminus; 
a putative pleckstrin homology (PH) domain between these two domains and partially overlaps 
with them [139, 147].  ILK binds PINCH proteins through the N-terminal ankyrin repeats 
domain and binds parvin proteins through C-terminal kinase domain [143].   
Although ILK is identified as serine/threonine kinase which can phosphorylate β1 
intergrin, the kinase activity of ILK has remained elusive and controversial.  As a kinase, 
previous studies showed that ILK can directly phosphorylate Glycogen Synthase Kinase 3 (GSK-
3) in vitro and inhibit GSK-3 activity.  In addition, kinase-active ILK can phosphorylate 
PKB/Akt on serine 473 by a PI3K-dependent fashion, whereas kinase-deficient ILK severely 
inhibits endogenous phosphorylation of PKB/Akt on serine 473 [148-149].  Mutations on serine 
or threonine of ILK have been described to abrogate the kinase activity in vitro.  S343A, R211A, 
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K220A/M have all been shown to abolish ILK catalytic activity [149-150].  The combination of 
two inactivating mutations (S343D and K220M) can abolish ATP binding activity, suggesting 
that these mutations might affect the activation status of downstream substrates such as Akt 
phosphorylation [151].  ILK deficient mice also displayed that the loss of ILK results in almost 
complete inhibition of phosphorylation on Ser 473 and significant inhibition of PKB/Akt 
activity, accompanied by significant stimulation of apoptosis [152].  However, other in vivo 
studies failed to replicate such findings.  Studies in Caenorhabditis elegans and Drosophila 
melanogaster found that kinase dead ILK mutants were capable of fully rescuing the severe 
phenotypes caused by ILK deletion in both species, indicating that ILK functions as a scaffold 
protein and not as a kinase [153-154].  In mouse models, it has been demonstrated that 
phosphorylation of PKB/Akt and GSK3-β is unaffected in ILK-deficient chondrocytes by 
Fässler’s group [155].  Therefore ILK has also been classified as a pseudokinase, a catalytically 
inactive remnant of an active kinase that uses its substrate recognition motif to interact with other 
proteins [156].  
The assembly of the IPP complex occurs before adhesion, and such an assembly is 
essential for their localization to cell-extracellular matrix adhesion sites, suggesting that the 
assembly in the cytoplasm is independent on adhesion signaling [157].  PINCH1 has been shown 
to be crucial to maintain the expression level of ILK, but not α-parvin, in this complex and 
regulate the functions of this complex in cell shape modulation, motility, and survival [158].  
Also, in our studies, blocking ILK expression by siRNA can down regulate PINCH1 expression.  
Interestingly in glomerular cells, TGF-β1 can regulate the IPP complex in a cell type-dependent 
manner: treatment with TGF-β1 in podocytes inhibits complex formation and promotes 
apoptosis by activating p38 protein kinase, whereas such treatment promotes the IPP formation 
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in mesangial cells [159].  It has been demonstrated that the IPP complex is important in 
controlling podocyte adhesion, morphology, and survival [144].  In this report, elevated levels of 
the IPP complex is found during podocyte differentiation and disruption of this complex leads to 
reduction of podocyte–matrix adhesion and foot process formation, and apoptosis [144].   
1.4.2 PINCH structure and function  
PINCH1 and PINCH2, also known as LIMS1 and LIMS2, are adaptor proteins that consist of 
five LIM domains.  Both isoforms bind to the N-terminal ankyrin repeat domain (ANK) repeats 
domain of ILK through their N-terminal LIM1 domain in an identical manner [160-161], so the 
determination of PINCH1- or PINCH2- containing IPP complex is probably dependent on the 
competition of available PINCH1 and/or PINCH2 [162]. 
The LIM domain is now recognized as a tandem zinc-finger structure which is comprised 
of approximately 55 amino acids with 8 highly conserved cysteine and histidine residues [163].  
Each LIM domain binds to two separate zinc ions separately through 4 conserved cysteine and 
histidine residues [164].  There seems to be no discrete consensus binding sequence or structural 
element for the LIM domain.  Besides ILK, adaptor protein Nck2 is another potential binding 
partner of PINCH1 whose interaction is mediated by the fourth LIM domain of PINCH and the 
third SH3 domain of Nck2 [165].  As an adaptor protein, Nck2 is associated with growth factor 
receptor kinase-signaling pathways, including EGF receptors, PDGF receptor-β, and IRS-1, by 
its SH2/SH3 domains, which indicates that Nck2 may mediate the connection between growth 
factor receptor-signaling pathways with the integrin-signaling pathways [165].  Nck also 
connects to the actin cytoskeleton and regulates the organization of actin cytoskeleton  [166].  In 
podocytes, it has been demonstrated that the nephrin phosphorylation event resulted in the 
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recruitment of Nck and assembly of actin filaments to regulate foot process formation and cell 
morphology [47-49].  Those reports might provide a pathway which bridges the integrin 
signaling with slit diaphragm signaling.  
The sequence of the C-terminal tail of PINCH reveals a putative leucine-rich nuclear 
export signal (NES) and an overlapping basic nuclear localization signal (NLS) [167].  It has 
been shown that PINCH shuttles between the cytoplasm and the nucleus in Schwann cells and 
dorsal root ganglia neurons, which suggests that PINCH may have an unrecognized function in 
controlling gene transcription and initiate new protein-protein interactions in the nucleus [167].  
Furthermore in Hela cells, PINCH1 C-terminal tail functions not only in the efficient localization 
of PINCH1 to cell-ECM adhesions but also in cell shape modulation and survival signaling after 
PINCH1 localizes to the adhesion sites [168].  
PINCH1 is ubiquitously expressed during early embryonic development and adult tissues 
[158].  Homozygous knockout of PINCH1 in mice leads to decreased cell proliferation and 
excessive cell death by E5.5 [169].  In Caenorhabditis elegans, depletion of UNC-97, the 
homologue of PINCH, results in defects in muscle adherens junctions and the mechanosensory 
functions of touch neurons [170].  In Drosophila melanogaster, muscle cells within embryos 
bearing mutations in the steamer duck (stck) gene, which encodes PINCH, show disturbed actin 
organization and cell-substratum adhesion, and failure of integrin-dependent epithelial cell 
adhesion in the wing [171].  All those phenotypes resemble the deletion of ILK or β1-integrin 
[172] and indicate that PINCH is essential to mediate integrin-dependent signaling during 
embryogenesis.  
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1.4.3 PINCH in diseases 
PINCH plays an important role in the suppression of apoptosis in tumor cells. 
Upregulation of PINCH has been reported in the initiation and development of several types of 
tumors, including oral squamous cell carcinoma and high-grade gliomas [173-175].  Depletion of 
PINCH1 by siRNA in human HeLa cervical carcinoma cells promotes apoptosis [168].  In the 
PINCH1 null mouse, apoptosis of endodermal cells and neural crest cells was detected in 
embryos [169, 176].  Mechanistically, PINCH1 promotes the activating phosphorylation of Src 
family kinases and ERK1/2, and removal of PINCH-1 in cancer cells inhibits SFK and ERK1/2 
activation and promotes Bim accumulation, resulting in activation of a Bim-dependent apoptosis 
pathway [177]. 
PINCH1 is expressed early in embryonic development and in the adult kidney; however, 
only a few studies regarding its regulation and function in renal cells is published.  Both PINCH1 
and PINCH2 have been shown to work with ILK and α-parvin to play essential roles on the 
regulation of adhesion, morphology, survival, and fibronectin matrix deposition in glomerular 
podocytes [144, 178]. PINCH1 has also been demonstrated as a downstream target of TGF-
β1/Smad signaling in tubular epithelial cells and to promote tubular epithelial to mesenchymal 
transition by an ILK dependent mechanism [125].  In vivo, PINCH1 upregulation is associated 
with tubular EMT and renal interstitial fibrogenesis induced by ureteral obstruction [125].  
Because LIM domain can bind to many other domains, more binding partners and functions 
remain to be identified for PINCH. 
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1.5 WNT/β-CATENIN SIGNALING PATYWAY 
1.5.1 Components of Wnt signaling 
Wnt proteins belong to a highly conserved family of secreted growth factors that play an 
essential role in embryonic development, homeostatic self-renewal in adult tissues and tumor 
formation [179]. The Wnt family contains 19 members, encoded by distinct genes, which are 
divided into 12 highly conserved subfamilies on the basis of sequence similarity [180].  They all 
share common structure features including a signal peptide for secretion, many potential 
glycosylation sites and multiple cysteine residues responsible for ensuring proper folding and 
secretion [181].   
Wnts are generated as precursors containing an amino-terminal hydrophobic signal 
peptide that directs the immature protein to the endoplasmic reticulum (ER).  In the ER, the 
signal peptide of Wnt proteins is cleaved and the proteins are palmitoylated on a conserved 
cysteine residue converting them into hydrophobic proteins.  This step is essential for Wnt 
protein biological activation, and mutation of the modification site results in inactivated proteins 
[180-181].   Wnt proteins also complex with Wntless in the Golgi to be efficiently mobilized to 
the outside of the cell [181]. 
Upon binding of secreted Wnt proteins to specific receptor complexes in target cells, 
Wnts can activate three different intracellular signaling pathways: the canonical pathway (T-cell 
factor (Tcf)/ β-catenin), the non-canonical pathway (planar cell polarity), and the Wnt/Ca2+ 
pathway [182-183].  Each of these pathways has their specific sets of target genes. 
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1.5.2 β-catenin in the canonical Wnt pathway 
β-catenin, the product encoded by CTNNB1 in humans, is a subunit of the cadherin protein 
complex.  It is an important cytoplasmic component of the classical cadherin adhesion complex 
that forms the adherens junction in epithelia and mediates cell-cell adhesion in many other 
tissues, and is a key signaling molecule in the canonical Wnt signaling pathway that controls cell 
growth and differentiation during both normal development and tumorigenesis.  β-catenin 
expresses a central armadillo-repeat containing domain through which it binds the cytoplasmic 
tail of classical cadherins. Meanwhile, it also binds alpha-catenin, which further links the 
cadherin complex to the actin cytoskeleton either directly or indirectly [184]. 
As shown in Figure 4, the activation of β-catenin is a complicated process involved in the 
interaction between the Wnts and their receptor complex, and the destruction complex, which 
interacts with β-catenin under inactivation conditions.  In the absence of a Wnt signal, β-catenin 
is associated with a scaffold protein Axin and adenomatous polyposis coli (APC) within the 
destruction complex, where β-catenin gets phosphorylated on a conserved set of serine and 
threonine residues at the amino-terminus by the casein kinase 1 (CK-1) and glycogen synthase 
kinase 3 (GSK-3).  This facilitates binding of the β-transducin repeat-containing protein (β-
TRCP), which subsequently mediates the ubiquitylation and efficient proteasomal degradation of 
β-catenin.  The degradation of β-catenin ensures the binding of Groucho proteins to Tcf proteins 
on the promoters and enhancers of Wnt target genes in the nucleus, thereby silencing the 
expression of the target gene and an array of biological response [181].  
When Wnts interact with cell surface receptor complexes that contain a Frizzled family 
member and low-density lipid receptor 5/6 (LRP5/6), Dishevelled (Dvl) is phosphorylated and 
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interacts with Frizzled to form a complex.  This complex stimulates the aggregation and 
phosphorylation of LRP by CK-1 at the membrane, leading to the relocation of Axin to the 
membrane and inactivation of the destruction complex.  Finally, β-catenin is free to accumulate 
and translocate into the nucleus, where it interacts with Tcf and recruits co-activators to facilitate 
the efficient activation of Wnt target genes [181]. 
Wnt signaling ultimately controls developmental fates through regulating the 
transcription of Tcf/β-catenin responsive target genes in specific cell types.  Wnt signals not only 
promote cell proliferation and tissue expansion, but also control fate determination or terminal 
differentiation of postmitotic cells.  These disparate events, proliferation and terminal 
differentiation, can be activated by Wnt in different cell types within the same structure, such as 
the hair follicle or the intestinal crypt [185].  The updated list of Wnts target genes can be found 
on the Wnt homepage (http://www.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes).  This 
list contains hundreds of genes regulated by Wnt signaling in humans and other species.  Among 
those genes, we can find that several components of the Wnt signaling pathway, such as 
Frizzleds, LRP, HSPG, Axin2, and TCF/Lef, are all regulated by the β-catenin/Tcf complex, 
which demonstrates that Wnt signaling is self regulated at several levels.  Mutations in β-catenin 
phosphorylation sites lead to the constitutive activation of the Wnt pathway and promote 
proliferation in human cancers [186].  Deregulation of the Wnt pathway is also related to several 
other types of human cancer and diseases [179]. 
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Figure 4.  The overview of Wnt/β-catenin signaling pathway. Figure taken from reference 
[181]. 
1.5.3 Regulation of Wnt/β-catenin signaling 
The activation of Wnt target genes and stabilization of β-catenin comprises a diverse set of 
biological processes involving many different proteins working together.  Given the complexity, 
it is easy to understand why aberrant regulation of this signaling activity at any step can affect 
the embryonic development and tissue renewal in stem cells and cancer cells [179, 185]. 
Wnt antagonists contain two functional classes, the sFRP class and the Dickkopf class. 
Members of the sFRP class bind directly to Wnts, thereby altering their ability to bind to the Wnt 
receptor complex; members of the Dickkopf (DKK) class inhibit Wnt signaling by binding to the 
LRP5/LRP6 component of the Wnt receptor complex.  Thus, in theory, those antagonists of the 
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sFRP class will inhibit both canonical and noncanonical pathways, whereas those of the DKK 
class specifically inhibit the canonical pathway [187].  The DKK family comprises four members 
(DKK-1 to DKK-4).  DKKs contain two characteristic cysteine-rich domains (Cys-1 and Cys-2) 
separated by a linker region of variable length.  Cys-2, in particular, is highly conserved among 
all members of the family and contains 10 conserved cysteine residues [188].  DKK-1, as a 
secretory protein, binds to the Wnt binding domain of LRP6 and forms a ternary complex with 
LRP-6 and Kremen (KRM) to lead to the endocytosis of the whole receptor complex [189-190].  
DKK-1 inhibits Wnt-induced stabilization of β-catenin and β-catenin/Tcf-dependent 
transcription of both artificial and endogenous genes in mammalian and amphibian cells, 
respectively [191-192].  In the kidney, DKK-1 blocks the expression of Wnt target genes, such as 
Twist, LEF1, c-myc and fibronectin and ameliorates renal fibrosis after obstructive injury in vivo 
[193].  On the other hand, DKK-1 is also a target of the β-catenin/TCF pathway and highly 
regulated on the transcriptional level as the direct feed back control of Wnt stimulation [194].   
1.5.4 Wnt/β-catenin signaling in kidney diseases and podocyte injury 
Wnt/β-catenin signaling is intimately involved in kidney development.  The genetic deletions of 
Wnt9b or Wnt4 in mice lead to severe kidney hypoplasia and an arrest of tubulogenesis at the 
stage of the pretubular aggregate with incomplete nephron formation [195-196].  Conditional β-
catenin knockout in the metanephric mesenchyme results in marked renal hypoplasia, reduction 
of nephron numbers, and down regulation of β-catenin/TCF target genes, including pax8, Wnt4, 
Fgf8 and Lhx1 [197].  Together, the data indicate that Wnt/β-catenin signaling is crucial for 
nephron development. 
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In normal adult kidney, Wnt signaling turns to be silenced [193].  However, 
overexpression of diverse Wnts and β-catenin are observed in a variety of kidney diseases 
originated from both the glomruli and tubulointerstitium [198].  Patients treated with lithium, a 
pharmacologic activator of β-catenin, have shown increased proteinuria, nephritic syndrome and 
progressive nephropathy, which is closely associated with the duration and cumulative dose 
[199-200].  Moreover, increased expressions of Wnt1 and β-catenin are found in the podocytes 
of patients with diabetic nephropathy and focal segmental glomerulosclerosis (FSGS) [201].  In 
mouse models, all of Wnt family members except Wnt5b, Wnt8b and Wnt9b are upregulated in 
fibrotic kidneys after unilateral ureteral obstruction (UUO), compared with sham normal kidney 
[193].  Consistently, the expression of β-catenin and its targets genes, such as c-Myc, Twist, 
LEF-1, and fibronectin are all upregulated in this model [193].  In the murine model of podocyte 
injury, adriamycin can induce proteinuria and activation of Wnt/β-catenin signaling, and ectopic 
expression of exogenous Wnt1 gene can exacerbate podocytes injury and proteinuria [201].  
Moreover, in the same report, it was shown that podocyte-specific deletion of β-catenin protects 
against development of albuminuria after podocyte injury induced by adriamycin.  Similarly, 
recent studies also demonstrate an induction of Wnt2 expression in a rat model of podocyte 
injury induced by puromycin aminonucleoside [202].  In both reports, the expression level of 
Snail1 is induced and associated with upregulation of Wnts and β-catenin in injured podocytes, 
which leads to the suppression of nephrin and podocytes dysfunction.  Together with the data 
from UUO model, it is conceivable that Wnt/β-catenin signaling may play a critical role in the 
pathogenesis of both podocyte injury and interstitial fibrosis, and therefore targeting this 
signaling could represent a novel class of therapeutic remedies for the treatment of proteinuric 
and fibrotic nephropathies. 
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2.0  PINCH1 IS TRANSCRIPTIONAL REGULATOR THAT INTERACTS WITH 
WT1 AND REPRESSES PODOCALYXIN EXPRESSION 
2.1 ABSTRACT 
PINCH1, an adaptor protein containing five LIM domains, plays an important role in regulating 
the integrin-mediated cell adhesion, migration and epithelial-mesenchymal transition.  Here we 
show that expression of PINCH1 in cultured podocytes was induced by TGF-β1, a fibrogenic 
cytokine that promotes podocyte dysfunction and proteinuria.  Interestingly, increased expression 
of PINCH1 not only localized at the sites of focal adhesions, but also underwent nuclear 
translocation after TGF-β1 stimulation.  This nuclear translocation of PINCH1 was apparently 
dependent on the putative nuclear export/localization signals (NES/NLS) at its C-terminus, as 
deletion or site-directed mutation of this sequence abolished its cytoplasmic-nuclear shuttling.  
Co-immunoprecipitation and pull-down experiments revealed that PINCH1 interacted with WT1, 
a transcription factor that is essential for directing podocyte-specific gene expression in adult 
kidney.  Interaction of PINCH1 and WT1 was mediated by the LIM1 domain of PINCH1 and C-
terminal zinc-finger domain of WT1, which led to the suppression of the WT1-mediated 
podocalyxin expression in podocytes.  PINCH1 also repressed podocalyxin gene transcription in 
a promoter-luciferase reporter assay.  In vivo, ectopic expression of TGF-β1 in mice also 
promoted nuclear translocation of PINCH1 and its interaction with WT1.  These results indicate 
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that PINCH1 can shuttle into the nucleus from cytoplasm in podocytes, wherein it interacts with 
WT1, leading to suppression of the podocyte-specific podocalyxin gene expression.  Our studies 
reveal that PINCH1 could act as a transcriptional regulator through interacting with nuclear 
WT1.   
2.2 MATERIALS AND METHODS 
2.2.1 Cell culture and treatment  
The conditionally immortalized human podocyte cell line was kindly provided by Dr. M. Saleem 
(University of Bristol, Bristol, UK) [203].  To propagate podocytes, cells were cultured at 33°C 
in RPMI-1640 medium supplemented with 10% fetal bovine serum and a mixture of insulin, 
transferrin and sodium selenite (ITS) (cat. no. I3146; Sigma, St. Louis, MO).  To induce 
differentiation, podocytes were grown under nonpermissive conditions at 37oC to inactivate the 
SV40 large T antigen.  Podocytes were treated with recombinant TGF-β1 at the concentration of 
2 ng/ml, unless otherwise indicated.  For some studies, podocytes were transiently transfected 
with various PINCH1 expression vectors by using Lipofectamine 2000 reagent (Invitrogen, 
Carlsbad, CA), as described previously [204].  Of note, pilot experiments indicated that human 
podocytes were relatively more efficient for transfection, compared to their mouse counterparts.   
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2.2.2 Animal models  
Male BALB/c mice that weighed approximately 18 to 20 g were purchased from Harlan Sprague 
Dawley (Indianapolis, IN).  For delivery of mouse TGF-β1 gene, constitutively active TGF-β1 
expression plasmid (pCA-TGF-β1), in which two cysteines at the positions 223 and 225 were 
mutated into serines, was injected intravenously at 0.3 mg/kg body wt by use of a 
hydrodynamics-based in vivo gene transfer approach, as described previously [205-206].  
Control mice were administered an injection of empty vector pcDNA3 plasmid in an identical 
manner.  Mice were sacrificed at day 1 and day 2 after injection, and kidney tissues were 
collected for various analyses.  Animal protocols were approved by the Institutional Animal Care 
and Use Committee at the University of Pittsburgh. 
2.2.3 Isolation of glomeruli 
Glomeruli were isolated using a differential serving technique from mouse kidneys according to 
the method described elsewhere [207].  Briefly, the kidneys were excised and pressed with a 
spatula through a stainless steel screen of # 100 mesh and rinsed with 1% albumin in cold 
phosphate-buffered saline (PBS-A) through successive screens of #200 mesh and #282 mesh, 
respectively.  The glomeruli were collected on the #282-mesh screen and suspended in PBS-A.  
After centrifugation at 200g for 10 min, the isolated glomeruli (purity, ~80%) were collected for 
subsequent analyses.    
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2.2.4 Construction of various expression vectors  
Various expression vectors with different epitope-tags were constructed using routine molecular 
cloning techniques.  Flag- and GFP-tagged PINCH1 expression vectors (pFlag-PINCH1 and 
pGFP-PINCH1), as well as GFP-tagged WT1 (pGFP-WT1) were constructed in the pcDNA3-
based expression vector under the control of CMV promoter.  The expression vector for WT1 (-
KTS) without KTS was kindly provided by Dr. D. Haber (Massachusetts General Hospital, 
Charlestown, MA).  The expression vector for truncated PINCH1 without NES/NLS (pFlag-
PINCH1-∆NES) was constructed by PCR using the wild-type PINCH1 expression plasmid 
(pFlag-PINCH1-wt) as a template.  The expression vectors for mutant PINCH1 with either a 
single amino acid mutation (pFlag-PINCH1-M1) or three amino acid mutation in the NES/NLS 
motif (pFlag-PINCH1-M3) were made by using QuikChange II XL site-directed mutagenesis kit 
(Stratagene, La Jolla, CA).  The expression plasmid harboring constitutively active TGF-β1 
(pCA-TGF-β1) contained two cysteine to serine mutations at the positions 223 and 225 
(C223S/C225S).  This expression vector was made by using QuikChange II XL site-directed 
mutagenesis kit, and it produces bioactive TGF-β1 that does not require acid activation, as 
previously reported [208].  The correct sequences of different expression vectors were confirmed 
by sequencing at the DNA Sequencing Core Facility of the University of Pittsburgh.   
2.2.5 RT-PCR and real-time PCR 
Total RNA was extracted using the TRIzol RNA isolation system (Invitrogen, Carlsbad, CA).  
The first strand of cDNA was synthesized using 2 µg of RNA in 20 µl of reaction buffer by 
reverse transcription using AMV-RT (Promega, Madison, WI) and random primers at 42°C for 
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30 min.  PCR was carried out using a standard PCR protocol with 1 µl aliquot of cDNA, 
HotStarTaq polymerase (Qiagen, Valencia, CA) and specific primer pairs.  The sequences of the 
primer pairs were as shown in Table 2.   For quantitative determination of mRNA levels, a real-
time RT-PCR was performed on ABI PRISM 7000 Sequence Detection System (Applied 
Biosystems, Foster City, CA), as described previously [209].  The PCR reaction mixture in a 25 
µl volume contained 12.5 µl of 2x SYBR Green PCR Master Mix (Applied Biosystems), 10 µl 
of diluted RT product (1: 10), and 0.5 µM sense and antisense primer sets.  PCR reaction was run 
by using standard conditions[209].  After sequential incubations at 50°C for 2 min and 95°C for 
10 min, respectively, the amplification protocol consisted of 40 cycles of denaturing at 95°C for 
15 sec, and annealing and extension at 60°C for 60 sec.  The mRNA levels of various genes were 
calculated after normalizing with β-actin.   
 
Table 2.  Nucleotide sequences of the primers used for RT-PCR 
Human gene Primer sequence of sense Primer sequence of anti-sense 
PINCH1 CCGCTGAGAAGATCGTGAAC GGGCAAAGAGCATCTGAAAG 
podocalyxin GAGCAGTCAAAGCCACCTTC TGGTCCCCTAGCTTCATGTC 
WT1 GCGGAGCCCAATACAGAATA TTATTGCAGCCTGGGTAAGC 
GAPDH 
TGAAGGTCGGAGTCAACGGA 
TTTGGT 
CATGTGGGCCATGAGGTCCA 
CCAC 
β-actin AGGCATCCTCACCCTGAAGTA CACACGCAGCTCATTGTAGA 
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2.2.6 Western blot analysis  
Cultured human podocytes were lysed in SDS sample buffer.  The isolated glomeruli were 
pooled and lysed with radioimmunoprecipitation assay buffer containing 1% NP-40, 0.1% 
sodium dodecyl sulfate, 100   μg/ml phenylmethylsulfonyl fluoride, 1% protease inhibitor 
cocktail, and 1% phosphatase I and II inhibitor cocktail (Sigma) in phosphate buffered saline on 
ice. The supernatants were collected after centrifugation at 13,000 × g at 4 °C for 20 min.  
Protein expression was analyzed by Western blot analysis as described previously [210].  The 
primary antibodies used were as follows: anti-PINCH1 (cat. no. 612711; BD Transduction, San 
Jose, CA), anti-Flag M2 (cat. no. F1804; Sigma), anti-GFP (cat. no. ab290; Abcam, Cambridge, 
MA), anti-WT1 (cat. no. sc-192; Santa Cruz Biotechnology, Santa Cruz, CA), anti-podocalyxin 
(cat. no. 39-3800; Invitrogen), anti-Histone H3 (cat. no. ab1791; Abcam), anti-TBP (TATA 
binding protein) (cat. no. ab181-100; Abcam), anti-actin (cat. no. sc-1616; Santa Cruz 
Biotechnology) and anti-α-tubulin (cat. no. T9026; Sigma). 
2.2.7 Immunoprecipitation  
Immunoprecipitation experiments were performed using similar methods as described previously 
[211].  Briefly, human podocyte lysates or mouse glomerular lysates were centrifuged at 12,000 
x g for 10 min at 4°C.  The supernatants were collected for immunoprecipitation.  After 
preclearing with normal host IgG, the lysates were immunoprecipitated overnight at 4°C with 4 
µg antibodies of anti-GFP, anti-Flag, anti-WT1, or normal rabbit or mouse IgG as controls, 
followed by precipitation with 60 µl protein A/G Plus-Agarose (Santa Cruz Biotechnology) for 3 
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h at 4°C.  The precipitated complexes were washed three times with lysis buffer and boiled for 5 
min in SDS sample buffer, followed by immunoblotting with various antibodies as indicated. 
2.2.8 Nuclear and cytoplasmic fractionation 
For preparation of nuclear protein, human podocytes were washed twice with cold phosphate-
buffered saline (PBS) and scraped off the plate with a rubber policeman.  After centrifugation, 
cell pellets were resuspended in Buffer A (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 nM KCl, 
0.5% NP-40 and 1% protease inhibitor cocktail (Sigma)) and lysed with homogenizer.  Cell 
nuclei were collected by centrifugation at 5,000 rpm for 15 min, and the supernatants were saved 
as cytoplasmic protein preparation.  After washing with Buffer B (10 mM HEPES pH 7.9, 1.5 
mM MgCl2, 10 nM KCl and 1% protease inhibitor cocktail), nuclei were lysed in SDS sample 
buffer.  Isolated mouse glomeruli were collected and washed twice with cold phosphate-buffered 
saline (PBS).  Nuclear protein preparation was made with NE-PER Nuclear and Cytoplasmic 
Extraction Reagents (Thermo Scientific, Rockford, IL).   
2.2.9 Purification of GST fusion protein and pull down assay  
Bacterial BL21 competent cells were transformed with GST and GST-WT1 fusion protein 
expression vectors, respectively.  Bacterial cells were cultured in LB medium containing 
ampicillin until the OD600 reaches 0.6-0.8, followed by adding 100 µM IPTG to induce 
recombinant protein expression.  After shaking at room temperature for 3 h, cell pellets were 
collected by spinning at 5,000 g for 10 min at 4°C.  Bacterial cell lysis was prepared with Rapid 
GST Inclusion Body Solubilization and Renaturation Kit (Cell Biolabs, Inc., San Diego, CA).  
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Gluthinoe-agarose beads were used to incubate with bacterial cell lysis overnight at 4°C.  Beads 
were washed three times with PBS containing 1% Triton X-100, and then incubated with 
podocyte lysates overnight at 4°C.  The precipitated complex were washed three times with lysis 
buffer and boiled for 5 min in SDS sample buffer, followed by immunoblotting with various 
antibodies as indicated.  
2.2.10 Luciferase reporter assay 
The reporter construct pGL3-podocalyxin, which contains the human podocalyxin promoter 
sequence and the sequence for firefly luciferase, was constructed as described elsewhere [70].  
After co-transfection with pGL3-podocalyxin and PINCH1 or/and WT1 expression vectors using 
Lipofectamine 2000 reagent (Invitrogen), podocytes were incubated for 48 h.  The supernatants  
of cell lysates were collected for the luciferase assay.  Luciferase activity was determined using 
the Dual Luciferase Assay System kit as described by the manufacturer's protocols (Promega).  
Relative luciferase activity of each group was reported as fold induction over the controls. 
2.2.11 Urinary albumin and creatinine assay 
Urine albumin level was measured by using a mouse Albumin ELISA Quantification kit, 
according to the manufacturer's protocol (Bethyl Laboratories, Montgomery, TX, USA). Urine 
creatinine was determined by a routine procedure as described previously [204]. 
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2.2.12 Statistical analysis  
All data examined were expressed as mean ± SEM.  Statistical analysis was performed using 
SigmaStat software (Jandel Scientific Software, San Rafael, CA, USA).  Comparison between 
groups was made using one-way analysis of variance (ANOVA), followed by Student-Newman-
Keuls test.  A P value of less than 0.05 was considered significant. 
2.3 RESULTS 
2.3.1 Induction of PINCH1 expression by TGF-β1 in glomerular podocyte 
We first examined the expression of PINCH1 in human podocytes after incubation with TGF-β1, 
a potent fibrogenic cytokine that is shown to induce podocyte dysfunction in a wide variety of 
proteinuric chronic kidney diseases [210, 212].  As shown in Figure 5A, PINCH1 mRNA was 
significantly induced in cultured human podocytes following TGF-β1 stimulation, as 
demonstrated by a quantitative, real-time RT-PCR assay.  This induction of PINCH1 mRNA 
started at 6 h, reached the peak at 24 h and sustained at least to 48 h after TGF-β1 treatment.  
Consistent with the mRNA expression, PINCH1 protein expression was also induced by TGF-β1 
in podocytes, as illustrated by Western blot analyses of the whole cell lysates (Figure 5, B and 
C).  TGF-β1 induced PINCH1 protein in a time-dependent manner, detected at 24 h and 
sustained at least to 72 h after treatment, time points that significantly lagged behind the mRNA 
induction.  The induction of PINCH1 expression also occurred in a dose-dependent fashion; and 
TGF-β1 induced its protein level at the concentration as low as 0.5 ng/ml, which reached the 
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peak at 2 ng/ml.  Further increase in TGF-β1 concentration did not result in additional induction 
of PINCH1 in podocytes. 
 
Figure 5.  TGF-β1 induces PINCH1 mRNA and protein expression in human podocytes.  A, 
Quantitative real-time RT-PCR reveals that TGF-β1 induced PINCH1 mRNA expression in a 
time-dependent manner.  PINCH1 mRNA levels were assessed by quantitative real-time RT-
PCR in human podocytes after TGF-β1 treatment (2 ng/ml) for various periods of time as 
indicated.  Data are presented as mean ± SEM of three experiments. *P < 0.05 versus controls.  
B and C, Western blot analyses demonstrate that TGF-β1 induced PINCH1 protein expression in 
a time- and dosage-dependent manner.  Human podocytes were treated with a fixed amount of 
TGF-β1 (2 ng/ml) for various periods of time as indicated (B) or with various concentrations of 
TGF-β1 for 48 h (C).  Total cell lysates were immunoblotted with specific antibodies against 
PINCH1 and actin, respectively.  
2.3.2 Nuclear translocation of PINCH1 in podocytes after TGF-β1 stimulation 
As an adaptor protein that binds to ILK, PINCH1 is primarily localized at the cell focal adhesion 
sites [213].  However, we found that PINCH1 was increasingly accumulated in the nuclei of 
podocytes after TGF-β1 stimulation.  Subcellular fractionation experiments revealed that nuclear 
PINCH1 was dramatically increased in a dose-dependent fashion, while its levels in the 
cytoplasmic preparation declined after TGF-β1 treatment (Figure 6A).  Quantitative 
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determination of the ratio of nuclear/cytoplasmic PINCH1 in podocytes after TGF-β1 treatment 
is presented in Figure 6B.  These results indicate that TGF-β1 not only induces PINCH1 
expression, but also triggers it to undergo nuclear translocation in podocytes.   
To rule out the possibility that an increased nuclear accumulation of PINCH1 is a 
consequence of its over-expression, we next tested whether TGF-β1 directly promotes the 
nuclear translocation of endogenous PINCH1.  To this end, we examined the nuclear 
accumulation of PINCH1 after a short incubation with TGF-β1, as it did not significantly induce 
PINCH1 protein expression until 24 h of incubation (Figure 5B).  As shown in Figure 7A, 
incubation with TGF-β1 for 1 to 3 h was sufficient to induce nuclear translocation of endogenous 
PINCH1, indicating that TGF-β1-induced nuclear translocation of PINCH1 is regulated by a 
mechanism independent of its abundance.   
To further confirm the nuclear translocation of PINCH1, we constructed an expression 
vector of GFP-PINCH1 fusion protein driven under CMV promoter.  After transfection of this 
GFP-PINCH1 expression vector for 24 h, podocytes were treated with TGF-β1 for 24 h.  We 
examined GFP-tagged PINCH1 subcellular distribution in podocytes using microscopy.  As 
shown in Figure 7B, under basal conditions, GFP-PINCH1 was mainly localized in the peri-
nuclear region of the cytoplasm, as well as at the focal adhesion sites in the periphery of 
spreading podocytes (Figure 7B, left panel, arrows), but little in the nuclei (Figure 7B, left panel, 
arrowhead).  However, GFP-tagged PINCH1 diminished in the peri-nuclear region and 
accumulated in the nuclei of podocytes after TGF-β1 treatment (Figure 7B, right panel, 
arrowhead), although it remained present at the focal adhesion sites (Figure 7B, right panel, 
arrow).  Quantitative calculation showed more than 60% of podocytes that exhibited GFP-
PINCH1 in the nuclei after TGF-β1 stimulation, a significant increase over the controls (Figure 
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7C).  To analyze this in a more quantitative way, we assessed nuclear and cytosol GFP-PINCH1 
abundance by Western blotting.  As shown in Figure 7D, nuclear GFP-PINCH1 was increased 
while its level in the cytoplasm declined, leading to a significant shift in the ratio of 
nuclear/cytoplasm GFP-PINCH1 after TGF-β1 treatment.  Since GFP-tagged PINCH1 is 
controlled under CMV promoter, which is not regulated by TGF-β1, these results indicate that 
TGF-β1 is able to induce nuclear translocation of PINCH1 apparently by an active process 
independent of its protein abundance. 
 
 
Figure 6.  TGF-β1 induces nuclear translocation of PINCH1 in human podocytes.  A, 
Western blot analyses show marked induction of PINCH1 protein in the nuclei of podocytes after 
TGF-β1 treatment.  Podocytes were incubated with TGF-β1 at various concentrations as 
indicated for 72 h.  Nuclear and cytoplasmic preparations were made and immunoblotted with 
specific antibodies against PINCH1, TATA box binding protein (TBP) and GAPDH, 
respectively.  B, Graphic presentation shows the relative ratio of the nuclear/cytoplasmic 
PINCH1 protein in podocytes after TGF-β1 treatment.  The value of the nuclear/cytoplasmic 
ratio of PINCH1 in the control group was set as 1.0.  Data are presented as mean ± SEM of four 
experiments. *P < 0.05, **P < 0.01 versus controls. 
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Figure 7.  PINCH1 nuclear translocation induced by TGF-β1 is regulated by a mechanism 
independent of its abundance.  A, Western blot analyses show nuclear accumulation of 
endogenous PINCH1 protein in podocytes after a short period of TGF-β1 treatment.  Podocytes 
were incubated with TGF-β1 (2 ng/ml) for short periods of time as indicated.  Nuclear and 
cytoplasmic proteins were separated and immunoblotted with specific antibodies against 
PINCH1, TBP and GAPDH, respectively.  B, Representative micrographs show the sub-cellular 
localization of GFP-PINCH1 fusion protein in control or TGF-β1-treated podocytes.  Podocytes 
were transfected with GFP-PINCH1 expression plasmid driven under CMV promoter for 24 h, 
and then incubated with TGF-β1 for additional 24 h at 2ng/ml.  Arrows indicate the localization 
of PINCH1 in the focal adhesion, while arrowheads denote the nuclear localization of PINCH1.  
C, Graphic presentation shows the percentage of the podocytes with positive nuclear GFP protein 
after TGF-β1 treatment.  Data are presented as mean ± SEM of three experiments. *P < 0.05 
versus controls.  D, Western blot analyses show an induction of GFP-PINCH1 protein in the 
nuclei of podocytes by TGF-β1.  Nuclear and cytoplasmic proteins were separated and 
immunoblotted with specific antibodies against PINCH1, TBP and GAPDH, respectively.  
  
2.3.3 Nuclear translocation of PINCH1 requires its putative NES/NLS motif 
Bioinformatics analysis revealed that PINCH1 harbors a leucine-rich, putative nuclear export 
signal (NES) and an overlapping nuclear localization signal (NLS), consisting of charged, mostly 
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basic amino acids such as lysine and arginine in its C-terminus, as previously reported [167, 
214].  Alignment of PINCH1 sequences derived from different species indicated that this region 
was highly conserved during evolution (Figure 8A).  To test whether this putative NES/NLS is 
responsible for mediating cytoplasmic-nuclear shuttling of PINCH1, we generated the truncated, 
Flag-tagged PINCH1 expression vector (pFlag-PINCH1-∆NES) in which the putative NES/NLS 
was deleted.  In addition, we also constructed a Flag-tagged, wild-type PINCH1 (pFlag-
PINCH1-wt), as well as two mutant PINCH1 expression vectors (pFlag-PINCH1-M1 and pFlag-
PINCH1-M3) by site-directed mutagenesis, as illustrated in Figure 8B.  These mutant PINCH1 
vectors contained either one or three leucine to alanine (L/A) point mutations in its putative 
NES/NLS motif, respectively (Figure 8B).  As shown in Figure 8C, deletion of putative 
NES/NLS almost completely blocked nuclear translocation of PINCH1, compared with the wild 
type PINCH1 controls.  Furthermore, mutations at three leucine positions (M3) in the NES/NLS 
motif also rendered PINCH1 unable to undergo cytoplasmic-nuclear shuttling (Figure 8C).  
However, a single mutation at one leucine position (M1) only marginally reduced the nuclear 
accumulation of PINCH1 (Figure 8C).  We further examined whether the putative NES/NLS is 
required for TGF-β1-induced nuclear translocation of PINCH1 by transfecting either wild-type 
or mutant PINCH1.  As demonstrated in Figure 8D, TGF-β1 could induce wild-type, but not 
mutant (M3), PINCH1 nuclear translocation in podocytes.  Therefore, it appears that the putative 
NES/NLS motif is required for mediating cytoplasmic-nuclear shuttling of PINCH1 under both 
basal and TGF-β1-stimulated conditions.   
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Figure 8.  Subcellular localization of PINCH1 is dictated by a putative motif in its C-
terminus. A, Amino acid sequence comparison reveals a conserved, overlapped, putative 
NES/NLS motif in the C-terminus of PINCH1 among different species including human, mouse, 
rat, and Drosophila. Alignments of the deduced amino acid sequences were performed by using 
PRALINE program. Color bar is a strength histogram that denotes the least to most conserved 
amino acids (least: dark blue, light blue, green, orange, red: most). B, Schematic diagram shows 
the structural domains of PINCH1 and construction of various PINCH1 mutants. Purple ovals 
indicate the five LIM domains. The position of a putative NES/NLS motif is shown by a bar, and 
the sequences of wild-type and mutant NES/NLS are given. C, Deletion or mutation of the 
putative NES/NLS blocks nuclear translocation of PINCH1 in podocytes. Human podocytes 
were transfected for 48 h with Flag-tagged wild-type PINCH1 (pFlag-PINCH1-wt), truncated 
PINCH1 without NES/NLS (p-Flag-PINCH1-ΔNES), PINCH1 with single amino acid mutation 
in the NES/NLS motif (pFlag-PINCH1-M1) and PINCH1 with three amino acids mutation in the 
NES motif (pFlag-PINCH1-M3), respectively. Nuclear and cytoplasmic proteins were separated 
and immunoblotted with antibodies against Flag. D, TGF-β1 treatment fails to induce nuclear 
translocation of PINCH1 with mutant NES/NLS. Podocytes were transfected with wild-type 
PINCH1 (pFlag-PINCH1-wt) or mutant PINCH1 (pFlag-PINCH1-M3) for 48 h, respectively, 
and then treated TGF-β1 (2 ng/ml) for 3 h. Nuclear and cytoplasmic proteins were separated and 
immunoblotted with antibodies against Flag.  
 
 
 54 
2.3.4 PINCH1 interacts with nuclear transcription factor WT1 
The finding that PINCH1 can shuttle into the nucleus prompted us to investigate its potential 
function in podocytes.  In view of the structural characteristics of PINCH1, which contains five 
LIM domains that mediate protein-protein interactions, we reasoned that PINCH1 might interact 
with other nuclear proteins that are important for podocyte biology.  Along this line, we revealed 
that PINCH1 could interact with WT1, a transcription factor that is exclusively expressed in 
podocytes in adult kidney.  As shown in Figure 9A, when Flag-tagged PINCH1 and GFP-tagged 
WT1 were co-expressed in podocytes, PINCH1 could be detected in the immunocomplexes 
precipitated by anti-GFP antibody.  In reciprocal experiments, after transfection of podocytes 
with Flag-tagged PINCH1 expression vector, endogenous WT1 was found in the 
immunocomplexes precipitated with anti-Flag antibody (Figure 9B).  These interactions between 
PINCH1 and WT1 appeared specific, as replacing specific antibodies with control IgG did not 
result in any binding (Figure 9, A and B).  Furthermore, physical interaction between 
endogenous PINCH1 and WT1 was detectable in podocytes after TGF-β1 stimulation (Figure 
9C), suggesting that PINCH1/WT1 complex formation actually occurs in patho-physiologically 
relevant conditions.   
To further confirm the specificity of PINCH1/WT1 interaction, we employed a GST-
fusion protein pull down experiment to examine the interaction between PINCH1 and WT1.  To 
this end, we generated a GST-WT1 fusion protein using a bacterial expression system.  As 
shown in Figure 9D, GST-WT1 fusion protein as well as GST control protein was purified.  
When these purified proteins were immobilized on glutathione-agarose beads and incubated with 
podocyte lysates, PINCH1 was pulled down and detected in the assay (Figure 9E), indicating a 
specific interaction between PINCH1 and WT1.  Of note, PINCH2, a protein that is closely 
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related to and shares a high degree of structural homology with PINCH1, also interacted with 
WT1 (Figure 9F).   
2.3.5 Delineation of the structural domains mediating PINCH1/WT1 interaction 
To define the structural domains responsible for mediating PINCH1/WT1 interaction, we 
generated a series of Flag-tagged, truncated PINCH1 expression vectors containing different 
LIM domains (Figure 10A).  After these constructs were co-transfected with GFP-tagged WT1 
expression vector into podocytes, physical interaction between different domains of PINCH1 and 
WT1 were assessed by co-immunoprecipitation.  As shown in Figure 10B, all truncated PINCH1 
proteins that contained LIM1 domain were detected in the immunocomplexes precipitated by 
anti-GFP antibody, whereas those PINCH1 proteins without LIM1 were not found in the 
immunoprecipitates under the same conditions.  These results indicate that the LIM1 domain of 
PINCH1 mediates its interaction with WT1 (Figure 10B). 
We also sought to determine the structural domain of WT1 that is involved in its 
interaction with PINCH1.  To this end, we generated two GFP-tagged expression vectors that 
contained either N-terminal, proline/glutamine-rich regulatory domain (1-315 aa) (WT1-NT) or 
C-terminal, DNA-binding domain (280-429 aa) (WT1-CT) containing four zinc fingers of the 
Kruppel-type (Figure 10C), respectively.  When these expression vectors were co-transfected 
with Flag-tagged PINCH1 construct in podocytes, potential interaction between truncated WT1 
and PINCH1 was examined by co-immunoprecipitation.  As shown in Figure 10, D and E, 
PINCH1 was only detected in the immunocomplexes in podocytes over-expressing GFP-tagged 
C-terminus of WT1 (WT1-CT), but not in the cells transfected with expression vector encoding 
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N-terminus of WT1 (WT1-NT).  Therefore, it appears clear that the C-terminal zinc-finger 
domains of WT1 mediate its interaction with PINCH1.  
 
 
Figure 9.  PINCH1 physically interacts with nuclear transcription factor WT1 in human 
podocytes.   A, Co-immunoprecipitation demonstrates a complex formation between PINCH1 
and WT1. Human podocytes were transfected with Flag-PINCH1 and GFP-WT1 for 48 h. Cell 
lysates were immunoprecipitated with specific antibody against GFP, followed by 
immunoblotting with antibody against Flag. IgG, control rabbit IgG.  B, Co-immunoprecipitation 
shows a complex formation between PINCH1 and WT1. Human podocytes were transfected 
with Flag-PINCH1 for 48 h. Cell lysates were immunoprecipitated with specific antibody against 
Flag, followed by immunoblotting with antibody against endogenous WT1. IgG, control mouse 
IgG.  C, Endogenous WT1 and PINCH1 interact after TGF-β1 treatment in podocytes. Human 
podocytes were treated with TGF-β1 (2 ng/ml) for 24 h. Cell lysates were immunoprecipitated 
with anti-WT1 antibody, followed by immunoblotting with anti-PINCH1. D, Coomassie blue 
staining shows the purified GST tagged proteins expressed in bacterial BL21. Lane 1, purified 
GST. Lane 2, purified GST-WT1 fusion protein.  E, Pull-down assay revealed a complex 
formation between PINCH1 and WT1. Purified GST-WT1 protein as well as control GST 
protein was incubated with podocyte lysate overnight, followed by immunoblotting with 
antibody against PINCH1.  F, PINCH2 also interacts with WT1. Cells were transfected with 
Flag-PINCH2 and GFP-WT1 for 48 h. IgG, control rabbit IgG. 
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Figure 10.  Delineation of the structural domains that mediate PINCH1/WT1 interaction.  
A, Schematic diagram shows the construction of various Flag-tagged PINCH1 expression 
vectors containing different LIM domains.  B, Co-immunoprecipitation indicates that the LIM1 
domain of PINCH1 mediates the interaction with WT1. Human podocytes were co-transfected 
with various Flag-tagged PINCH1 LIM domains and GFP-WT1 for 48 h. Cell lysates were 
immunoprecipitated with specific antibody against GFP, followed by immunoblotting with 
antibody against Flag. Asterisk (*) indicate positive interactions.  C, Diagram shows the 
constructions of GFP tagged WT1 fragments. The WT1 used is the isoform without KTS and 17 
aa encoded by exon 5 (WT1, -KTS, -17 aa). WT1-NT, N-terminal fragment of WT1 (1-315 aa); 
WT1-CT, C-terminal fragment of WT1 (280-429 aa).  D, Co-immunoprecipitation shows that 
PINCH1 interacted with WT1-CT, but not WT1-CT. Human podocytes were transfected with 
Flag-PINCH1 and either GFP-tagged WT1-NT or GFP-tagged WT1-CT for 48 h. Cell lysates 
were immunoprecipitated with specific antibody against GFP, followed by immunoblotting with 
anti- Flag. E, Expression of GFP-tagged WT1 fragments in podocytes after transfection were 
confirmed by Western blot analysis. 
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2.3.6 PINCH1 represses WT1-mediated podocalyxin expression   
To examine the potential consequence of PINCH1/WT1 interaction, we investigated the effects 
of PINCH1 on WT1-mediated gene expression.  Podocalyxin, a transmembrane protein that 
plays a crucial role in the maintenance of podocyte morphology and foot processes [215], is well 
characterized as a WT1 target gene.  Indeed, we found that ectopic expression of WT1 in 
podocytes significantly induced podocalyxin mRNA and protein expression (Figure 11, A 
through C).  However, co-transfection of PINCH1 largely abolished WT1-mediated podocalyxin 
induction.  Of note, PINCH1 had the tendency, although not significantly, to inhibit basal 
podocalyxin mRNA expression in the absence of exogenous WT1 (Figure11, A and B), 
suggesting that podocalyxin is also controlled by endogenous WT1 in podocytes.  Likewise, 
knockdown of PINCH1 increased podocalyxin mRNA expression in podocytes (Figure 11, D 
and E).  Therefore, it becomes clear that PINCH1 interacts with WT1, which leads to 
suppression of the WT1-mediated gene expression in podocytes. 
We futher investigated the effects of PINCH1 on podocalyxin gene transcription using a 
promoter-luciferase reporter assay.  A podocalyxin promoter luciferase reporter vector 
containing a putative WT1 response element at the nucleotide positions -1213 to -1227 was 
constructed, as previously reported [70].  We found that co-transfection of the WT1 expression 
vector significantly stimulated the podocylyxin promoter luciferase activity in podocytes, 
compared to empty vector pcDNA3 (Figure 11F).  However, when PINCH1 was co-expressed, 
the WT1-mediated podocalyxin promoter-luciferase activity was suppressed, compared with 
transfection with WT1 alone (Figure 11F).  Therefore, consistent with the suppression of 
podocalyxin protein and mRNA, PINCH1 also abolishes the WT1-mediated the transcription of 
podocalyxin gene.   
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Figure 11.  PINCH1 blocks WT1-mediated podocalyxin expression in human podocytes.  A, 
RT-PCR analyses demonstrate that PINCH1 blocked WT1-stimulated podocalyxin mRNA 
expression in podocytes.  Cells were transfected with expression vectors for PINCH1, WT1 or 
both, respectively. RT-PCR amplification of housekeeping GAPDH was performed in an 
identical manner to serve as controls.  B, Graphic presentation shows the relative PINCH1 
mRNA abundance in different groups after normalization with GAPDH. Data are presented as 
mean ± SEM of three independent experiments. *P < 0.05.  C, Western blot analyses show that 
PINCH1 blocked WT1-mediated podocalyxin protein expression. Human podocytes were 
transfected with different plasmids as indicated for 48 h. Total cell lysates were immunoblotted 
with specific antibodies against podocalyxin and actin, respectively.  D and E, Knockdown of 
PINCH1 in podocytes promotes podocalyxin expression. Human podocytes were transfected 
with either control or PINCH1-specific siRNA at 100nM.  The expression of PINCH1 (D) and 
podocalyxin (E) was assessed by quantitative RT-PCR. **P < 0.01 (n = 3).  F, PINCH1 
represses WT1-activated podocalyxin gene promoter activity.  Human podocytes were co-
transfected with different plasmids as indicated with luciferase - podocalyxin gene promoter 
reporter construct (pGL3-podocalyxin) for 48 h.  Equal amounts of DNA were present in each 
transfection.  Data are presented as mean ± SEM of three independent experiments. *P < 0.05. 
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2.3.7 PINCH1/WT1 interaction occurs in vivo and is associated with proteinuria 
To explore the pathophysiological relevance of PINCH1 nuclear translocation in vivo, we 
examined the endogenous PINCH1/WT1 interaction in mouse glomeruli after TGF-β1 
stimulation.  Expression plasmid encoding constitutively active TGF-β1 was administrated into 
mice through a single intravenous injection by using a hydrodynamic-based gene delivery 
approach, as previously described [205-206].  As shown in Figure 12A, PINCH1 also underwent 
nuclear translocation in the glomerular cells in vivo after TGF-β1 stimulation.  Furthermore, co-
immunoprecipitation demonstrated a physical interaction between endogenous PINCH1 and 
WT1 in the isolated glomeruli in vivo, which was induced by TGF-β1 in a time-dependent 
manner (Figure 12B).  Notably, PINCH1 abundance in the glomerular lysates was also slightly 
increased at 24 hours after pCA-TGF-β1 injection (Figure 12B, Input).  Of note, such a 
PINCH1/WT1 interaction was associated with proteinuria in mice (data not shown).  Taken 
together, it is clear that after stimulation with TGF-β1, endogenous PINCH1 also undergoes 
nuclear translocation and interacts with WT1 in vivo, which is associated with onset of 
proteinuria.   
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Figure 12.  PINCH1 undergoes nuclear translocation and forms interaction with WT1 in 
vivo.  A, PINCH1 undergoes nuclear translocation in glomerular cells. Glomeruli were isolated 
from mouse kidneys at 24 hours after injection of plasmids (pcDNA3 or pCA-TGF-β1). Nuclear 
and cytoplasmic proteins from the isolated glomeruli were prepared and immunoblotted with 
antibodies against PINCH1, histone H3 (H3) or GAPDH, respectively.  Numbers (1 and 2) 
indicate each individual glomerular preparation, which was made from a pool of kidneys from 
two mice.  B, PINCH1 interacts with WT1 in vivo. Glomerular lysates at different time points 
after injection of TGF-β1 expression plasmid were immunoprecipitated with anti-WT1 antibody, 
followed by immunoblotting with anti-PINCH1. Whole glomerular lysates were also 
immunoblotted with anti-PINCH1.   
 
2.4 DISSCUSSION 
PINCH1 is an adaptor/scaffolding protein that constitutively interacts with ILK and localizes at 
focal adhesion sites.  In this study, we provide evidence demonstrating that PINCH1 also 
functions as a transcriptional regulator by interacting with nuclear WT1, a podocyte-specific 
transcription factor that plays a pivotal role in the establishment and maintenance of the unique 
differentiated features of podocytes in adult kidney.  We show that PINCH1 is up-regulated in 
podocytes after stimulation with TGF-β1, translocates into the nucleus, wherein it binds to WT1 
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and suppresses the WT1-mediated gene transcription.  Our results uncover a novel pathway in 
which PINCH1 controls gene transcription by interacting with the nuclear transcription factor 
WT1 in podocytes.   
As a LIM-only adaptor protein, PINCH1 is a well known to interact with cytoplasmic 
ILK and modulates integrin signaling [216-217].  In glomerular podocytes, PINCH1 likely plays 
an imperative role in bridging the cell-cell slit diaphragm and cell-matrix integrin signaling by 
participating in the nephrin/ILK complex formation [211].  It is well established that PINCH1 
through its LIM1 domain binds to the ankyrin repeat domain of ILK [160], while its LIM4 
domain interacts with the third SH3 domain of Nck [165], another cytoplasmic adaptor protein 
that binds to nephrin through its SH2 domain [218-219].  As a result, PINCH1, together with 
Nck, essentially builds a physical connection between nephrin and ILK.  This notion is supported 
by an earlier observation that ILK is physically linked to nephrin, as shown by co-
immunoprecipitation and co-localization [211].  Conditional ablation of ILK in a podocyte-
specific fashion leads to aberrant nephrin distribution by disrupting this multi-component 
complex formation, thereby causing podocyte dysfunction, proteinuria, kidney failure and 
premature animal death [211].  Interestingly, ILK/PINCH1 complex formation is decreased in 
glomerular podocytes after treatment with TGF-β1 [159], although both ILK and PINCH1 are 
upregulated in these cells.  These observations support our present results that PINCH1 
undergoes nuclear translocation in podocytes after stress/injury.   
In view of the presence of a putative NES/NLS motif in its C-terminus, it is not 
completely surprising that PINCH1 undergoes cytoplasmic-nuclear shuttling.  Indeed, this 
NES/NLS motif is evolutionarily conserved, functionally important and obligatory for mediating 
nuclear translocation of PINCH1, as deletion or site-directed mutations of this motif effectively 
 63 
prevents cytoplasmic-nuclear shuttling of PINCH1 in podocytes under basal and TGF-β1-
stimulated conditions (Figure 8).  However, at this stage we cannot exclude the possibility that 
deletion or mutation of NES/NLS motif may cause a structural perturbation, leading to disruption 
of the PINCH1 function, as leucine residues in the motif may play a critical role in stabilizing the 
overall structure of the protein.   
It is conceivable that a small fraction of PINCH1 may be localized constitutively in the 
nuclei under basal conditions.  Along that line, there are three possible sub-cellular, nuclear, 
cytoplasmic and focal adhesion-associated, pools of PINCH1 in podocytes.  Each specific pool 
of PINCH1 may have different functions.  While the focal adhesion-associated PINCH1 may 
play a critical role in modulating cell adhesion, cell shape and survival [168], we show here that 
nuclear PINCH1 is instrumental in regulating gene transcription via its interaction with WT1.  
Cellular stress/injury after TGF-β1 treatment accelerates the rate of its cytoplasmic-nuclear 
shuttling, resulting in an increased accumulation of PINCH1 in the nuclei, but it does not appear 
to significantly affect the focal adhesion-associated PINCH1 (Figure 7B).  Nuclear accumulation 
of PINCH1 is unlikely a passive consequence of an increased overall level of its protein, since 
TGF-β1 also promotes nuclear translocation of PINCH1 after a short period of incubation (1-3 
hours) (Figure 7A) when significant PINCH1 induction was not evident (Figure 5B).  Such a 
PINCH1 shuttling between cytoplasm and nucleus is also reported in Schwann cells after chronic 
constriction injury in adult rats [167].  Consistently, several other LIM-containing proteins are 
found to be able to undergo cytoplasmic-nuclear shuttling [163, 220-221].  In this context, it is 
reasonable to conclude that PINCH1 is able to translocate into the nuclei, thereby initiating new 
protein-protein interactions and participating in the control of gene transcription in diverse 
circumstances.   
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One of the novel findings in the present study is the identification of WT1 transcription 
factor as the binding partner for PINCH1 in the nuclei.  Through defining the molecular details 
of PINCH1/WT1 interaction, it is revealed that the LIM1 domain of PINCH1 mediates its 
interaction with WT1, whereas the C-terminal zinc-finger domains of WT1 are responsible for its 
binding to PINCH1 (Figure 10).  Notably, the same LIM1 domain mediates PINCH1 interaction 
with ILK in the cytoplasm at the focal adhesion sites.  Therefore, LIM1 domain of PINCH1 is 
practically responsible for its interaction with either cytoplasmic ILK or nuclear WT1, depending 
on its specific localization within podocytes at a given setting.  Because WT1, a key transcription 
factor that is exclusively expressed in glomerular podocytes in adult kidney, plays a critical role 
in establishing the unique features of podocytes by inducing specific gene expression, such a 
PINCH1/WT1 interaction likely has a detrimental consequence.  Indeed, endogenous 
PINCH1/WT1 interaction actually occurs in podocytes after TGF-β1 stimulation both in vitro 
(Figure 9C) and in vivo (Figure 12B).  It should be noted that it remains to be determined what 
consequence can be caused directly by PINCH1/WT1 interaction.  Similarly, interaction between 
WT1 and the WT1-interacting protein (WTIP), another LIM-containing protein, is previously 
shown to lead to the suppression of WT1-mediated gene expression and podocyte dysfunction 
[220-221].   
PINCH1 cytoplasmic-nuclear shuttling and subsequent interaction with WT1 might 
influence the WT1-mediated gene expression in podocytes.  In that regard, it is revealed that 
PINCH1 regulates the expression of podocalyxin, a well-characterized podocyte-specific protein 
that is transcriptionally controlled by WT1.  Earlier in vivo and in vitro studies demonstrate that 
WT1 level and activity directly dictate podocalyxin expression in glomerular podocytes [70, 73, 
215].  Indeed, ectopic expression of WT1 in cultured podocytes induces podocalyxin mRNA and 
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protein expression (Figure 11).  Given that PINCH1 binds to the zinc-finger domains of WT1, it 
is not unexpected that over-expression of PINCH1 abolishes WT1-mediated podocalyxin 
expression, while knockdown of PINCH1 induced podocalyxin expression (Figure 11).  
Podocalyxin is a CD34-related, transmembrane, sialoglycoprotein that contains a highly charged 
cytoplasmic tail [215].  It is connected to the cortical actin cytoskeleton via ezrin and Na+/H+-
exchanger regulatory factor 2 (NHERF2) and plays an essential role in maintaining the foot 
process structure and filtration function.  Disruption of podocalyxin/NHERF2/ezrin/actin 
interactions leads to pathologic conditions associated with changes in podocyte foot processes 
[222].  Consistently, podocalyxin-deficient mice fail to form foot processes and slit diaphragm 
and die within 24 hours after birth with anuric renal failure [64].  Therefore, suppression of 
WT1-medated gene expression by PINCH1 could be a potential pathway leading to podocyte 
dysfunction.  
In summary, we have shown that PINCH1, an adaptor protein that is associated with ILK 
at the focal adhesion site, can undergo cytoplasmic-nuclear shuttling in podocytes.  Nuclear 
PINCH1 via its LIM1 domain interacts with a new partner WT1.  By interacting with the zinc 
finger domains of WT1, PINCH1 effectively blocks WT1-mediated gene transcription.  Our data 
provide a proof of principal that PINCH1 can function as a transcriptional regulator by 
repressing WT1-mediated gene expression, and these studies could set a foundation for future 
investigations.   
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3.0  WNT/β-CATENIN SIGNALING MEDIATES TGF-β1-DRIVEN PODOCYTE 
INJURY AND PROTEINURIA 
3.1 ABSTRACT 
TGF-β1, a potent fibrogenic cytokine, is upregulated in virtually all kinds of chronic kidney 
diseases, and its over-expression in transgenic mice is associated with podocyte injury and 
proteinuria.  However, how TGF-β1 induces podocyte dysfunction and proteinuria in vivo 
remains poorly understood.  Here we show that Wnt/β-catenin signaling plays a critical role in 
mediating podocyte injury and proteinuria induced by TGF-β1.  In vitro, treatment with TGF-β1 
induced the expression of several Wnts, predominantly Wnt1, and activated β-catenin in mouse 
podocytes.  Wnt antagonist Dickkopf-1 (DKK1) blocked TGF-β1-induced β-catenin activation 
and preserved nephrin expression.  In vivo, ectopic expression of constitutively active TGF-β1 
induced Wnt1 expression, activated glomerular β-catenin, and upregulated its downstream target 
genes such as Snail1, MMP-7, MMP-9, desmin and fibroblast-specific protein 1 (Fsp1), which 
led to podocyte injury and proteinuria.  Consistently, concomitant expression of DKK1 gene 
abolished β-catenin activation in mouse glomeruli, inhibited the TGF-β1-triggered Wnt/β-
catenin target genes including Snail1, MMP-7, MMP-9, LEF-1 and plasminogen activator 
inhibitor-1, and reduced albuminuira.  These results establish a role for Wnt/β-catenin signaling 
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in the pathogenesis of podocyte injury.  Our data also suggest that this signaling pathway could 
be exploited as a therapeutic target for the treatment of proteinuric kidney diseases. 
3.2 MATERIALS AND METHODS 
3.2.1 Cell culture and treatment 
The conditionally immortalized mouse podocyte cell line was kindly provided by Dr. Peter 
Mundel (Mount Sinai School of Medicine, New York, NY), as described previously [42].  To 
propagate podocytes, cells were cultured at 33°C in RPMI-1640 medium supplemented with 
10% fetal bovine serum (FBS) and recombinant IFN-γ (Invitrogen, CarIsbad, CA).  To induce 
differentiation, podocytes were grown under nonpermissive conditions at 37oC in the absence of 
IFN-γ.  Podocytes were treated with recombinant TGF-β1 (R & D Systems, Minneapolis, MN) at 
the concentration of 2 ng/ml, unless otherwise indicated.  Recombinant mouse DKK1 (R&D 
Systems, Inc., Minneapolis, MN) was used for pretreatment at 40 or 200 ng/ml for 1 h, followed 
by incubation with TGF-β1 for 24 h.  For some studies, podocytes were transiently transfected 
with either HA-tagged Wnt1 expression vector (pHA-Wnt1; Upstate Biotechnology, Lake 
Placid, NY), or Flag-tagged N-terminal truncated, stabilized β-catenin expression vector (pDel-
β-cat) by using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA), as described previously 
[204].    
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3.2.2 Animal models  
Male BALB/c mice that weighed approximately 18 to 20 g were purchased from Harlan Sprague 
Dawley (Indianapolis, IN).  For delivery of mouse TGF-β1 gene, constitutively active TGF-β1 
expression plasmid (pCA-TGF-β1), in which two cysteines at the positions 223 and 225 were 
mutated into serines, was injected intravenously at 0.3 mg/kg body wt by using of a 
hydrodynamics-based in vivo gene transfer approach, as described previously [205-206].  For 
delivery of human DKK1 gene, naked DKK1 expression plasmid (pFlag-DKK1; provided by Dr. 
Xi He, Harvard Medical School, Boston, MA) was injected intravenously at 2 mg/kg body wt by 
using the same approach with or without pCA-TGF-β1 plasmid.  Control mice were 
administered an injection of empty vector pcDNA3 plasmid in an identical manner.  Mice were 
sacrificed at day 1 and day 2 after injection, and kidney tissues were collected for various 
analyses. One part of the kidneys was fixed in 10% phosphate-buffered formalin for histologic 
and immunohistochemical studies after paraffin embedding. Another part was immediately 
frozen in OCT compound for cryosection. The remaining kidneys were snap-frozen in liquid 
nitrogen and stored at -80°C for protein extractions.  Animal protocols were approved by the 
Institutional Animal Care and Use Committee at the University of Pittsburgh. 
3.2.3 Isolation of glomeruli  
Glomeruli were isolated by differential sieving technique according to the method described 
elsewhere [207].  Briefly, the kidneys were excised and pressed with a spatula through a stainless 
steel screen of #100 mesh and rinsed with 1% albumin in cold phosphate-buffered saline (PBS-
A) through successive screens of #200 mesh and #282 mesh, respectively.  The glomeruli were 
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collected on the #282-mesh screen and suspended in PBS-A.  After centrifugation at 200 g for 10 
min, the isolated glomeruli (purity, ~80%) were collected for subsequent analyses.  
3.2.4 Urinary albumin and creatinine assay 
Urinary albumin level was measured by using a mouse Albumin ELISA Quantification kit, 
according to the manufacturer's protocol (Bethyl Laboratories, Montgomery, TX, USA). Urine 
creatinine was determined by a routine procedure as described previously [204]. 
3.2.5 Construction of pCA-TGF-β1 vector 
The expression plasmid vectors containing mouse wild-type TGF-β1 (pWT-TGF-β1), N-
terminus truncated TGF-β1 (pNT-TGF-β1) and constitutively active TGF-β1 (pCA-TGF-β1) 
were constructed by using standard molecular cloning techniques.  The pCA-TGF-β1 vector 
contained two cysteine to serine mutations at the positions 223 and 225 (C223S/C225S).  This 
expression vector was made by using QuikChange II XL site-directed mutagenesis kit, and it 
produces bioactive TGF-β1 that does not require acid activation, as previously reported [208].  
The correct sequences of different expression vectors were confirmed by sequencing at the DNA 
Sequencing Core Facility of the University of Pittsburgh.   
3.2.6 RT-PCR and real-time PCR  
Total RNA was extracted using the TRIzol RNA isolation system (Invitrogen, Carlsbad, CA).  
The first strand of cDNA was synthesized using 2 µg of RNA in 20 µl of reaction buffer by 
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reverse transcription using AMV-RT (Promega, Madison, WI) and random primers at 42°C for 
30 min.  PCR was carried out using a standard PCR protocol with 1 µl aliquot of cDNA, 
HotStarTaq polymerase (Qiagen, Valencia, CA) and specific primer pairs.  The sequences of the 
primer pairs were are shown in Table 3.  For quantitative determination of mRNA levels, a real-
time RT-PCR was performed on ABI PRISM 7000 Sequence Detection System (Applied 
Biosystems, Foster City, CA), as described previously [209]  The PCR reaction mixture in a 25 
µl volume contained 12.5 µl of 2x SYBR Green PCR Master Mix (Applied Biosystems), 10 µl 
of diluted RT product (1: 10), and 0.5 µM sense and antisense primer sets.  PCR reaction was run 
by using standard conditions [209].  After sequential incubations at 50°C for 2 min and 95°C for 
10 min, respectively, the amplification protocol consisted of 40 cycles of denaturing at 95°C for 
15 sec, and annealing and extension at 60°C for 60 sec.  The mRNA levels of various genes were 
calculated after normalizing with β-actin.   
Table 3.  Nucleotide sequences of the primers used for RT-PCR 
Mouse 
gene 
Primer sequence of sense Primer sequence of anti-sense 
nephrin CCCAACACTGGAAGAGGTGT CTGGTCGTAGATTCCCCTTG 
Snail ATTCTCCTGCTCCCACTGC ACTCTTGGTGCTTGTGGAG 
MMP9 CACCACCACAACTGAACCAC CTCAGAAGAGCCCGCAGTAG 
MMP7 TAGGCGGAGATGCTCACTTT TTCTGAATGCCTGCAATGTC 
FSP-1 AGCTACTGACCAGGGAGCTG TCATTGTCCCTGTTGCTGTC 
PAI-1 TCATCAATGACTGGGTGGAA TGCTGGCCTCTAAGAAAGGA 
LEF-1 AAATGGGTCCCTTTCTCCAC CATCTGACGGGATGTGTGAC 
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β-actin CAGCTGAGAGGGAAATCGTG CGTTGCCAATAGTGATGACC 
Wnt1 GCCCTAGCTGCCAACAGTAGT GAAGATGAACGCTGTTTCTCG 
Wnt2 AGAGTGCCAACACCAGTTCC TACAGGAGCCACTCACACCA 
Wnt2b TTGTGTCAACGCTACCCAGA ACCACTCCTGCTGACGAGAT 
Wnt3 GGGGCGTATTCAAGTAGCTG GTAGGGACCTCCCATTGGAT 
Wnt3a TTCTTACTTGAGGGCGGAGA CTGTCGGGTCAAGAGAGGAG 
Wnt4 CGAGGAGTGCCAATACCAGT GTCACAGCCACACTTCTCCA 
Wnt5a CCCAGTCCGGACTACTGTGT TTTGACATAGCAGCACCAGTG 
Wnt5b TCTCCGCCTCACAAAAGTCT CACAGACACTCTCAAGCCCA 
Wnt6 TTCGGGGATGAGAAGTCAAG CGGCACAGACAGTTCTCCTC 
Wnt7a GACAAATACAACGAGGCCGT GGCTGTCTTATTGCAGGCTC 
Wnt7b ACAGGAGGGTGGGGATAGA GAAACAGCCCAGGAAACCGT 
Wnt8a CTGACTACTGCAACCGCAAC TGACAGTGCAACACCACTGA 
Wnt8b CCAGAGTTCCGGGAGGTAG GAGATGGAGCGGAAGGTGT 
Wnt9a CCCCTGACTATCCTCCCTCT GATGGCGTAGAGGAAAGCAG 
Wnt9b GGGTGTGTGTGGTGACAATC TCCAACAGGTACGAACAGCA 
Wnt10a GCGCTCCTGTTCTTCCTACT ATGCCCTGGATAGCAGAGG 
Wnt10b TCAGTCGGGCTCTAAGCAAT TGGTGCTGACACTCGTGAAC 
Wnt11 TGCTTGACCTGGAGAGAGGT AGCCCGTAGCTGAGGTTGT 
Wnt16 CCCTCTTTGGCTATGAGCTG TACTGGACATCATCCGAGCA 
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3.2.7 Western blot analysis  
Cultured mouse podocytes were lysed in SDS sample buffer.  The isolated glomeruli were 
pooled and lysed with radioimmunoprecipitation assay buffer containing 1% NP-40, 0.1% 
sodium dodecyl sulfate, 100   μg/ml phenylmethylsulfonyl fluoride, 1% protease inhibitor 
cocktail, and 1% phosphatase I and II inhibitor cocktail (Sigma) in phosphate buffered saline on 
ice. The supernatants were collected after centrifugation at 13,000 × g at 4 °C for 20 min.  
Protein expression was analyzed by Western blot analysis as described previously [210].  The 
primary antibodies used were as follows: anti-β-catenin (cat. no. 6101541; BD Transduction, San 
Jose, CA), anti-dephosphorylated, active β-catenin (cat. no. 05-665; Millipore, Billerica, MA), 
anti-GFP (cat. no. ab290; Abcam, Cambridge, MA), anti-phopsho-Smad3 (Ser423/425) (cat. no. 
9514; Cell Signaling, Boston, MA), anti-Smad1/2/3 (cat. no. sc-7960; Santa Cruz Biotechnology, 
Santa Cruz, CA), anti-PAI-1 (sc-5297; Santa Cruz Biotechnology), anti-WT1 (ab15249; Abcam) 
anti-Histone H3 (ab1791; Abcam),  anti-actin (sc-1616; Santa Cruz Biotechnology) and anti-α-
tubulin (T9026; Sigma). 
3.2.8 Nuclear and cytoplasmic fractionation 
For preparation of nuclear protein, isolated mouse glomeruli were collected and washed twice 
with cold phosphate-buffered saline (PBS).  Nuclear protein preparation was made with NE-PER 
Nuclear and Cytoplasmic Extraction Reagents, according to the protocols specified by the 
manufacturer (Thermo Scientific, Rockford, IL).   
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3.2.9 Immunofluorescent and Immunohistochemical staining 
Kidney cryosections at 3-μm thickness were fixed for 15 min in 4% paraformaldehyde, followed 
by permeabilization with 0.2% Triton X-100 in PBS for 10 min at room temperature.  After 
blocking with 10% donkey serum for 60   min, slides were immunostained with primary 
antibodies against nephrin (Fitzgerald Industries International, Concord, MA, USA), or 
phosphorylated Smad3 (Ser423/425) (cat. no. 9514, Cell Signaling).  To visualize the primary 
antibodies, cells were stained with Cy2 or Cy3-conjugated secondary antibodies (Sigma). Slides 
were viewed with a Nikon Eclipse E600 Epi-fluorescence microscope equipped with a digital 
camera (Melville, NY). In each experimental setting, images were captured with identical light 
exposure times.  Immunohistochemical staining of kidney sections was performed by an 
established protocol [223].  Paraffin-embedded sections were stained with polyclonal rabbit anti–
β-catenin antibody (ab-15180; Abcam, Cambridge, MA).  Slides were viewed with a Nikon 
Eclipse E600 microscope equipped with a digital camera (Melville, NY). 
3.2.10 Statistical analysis 
All data examined were expressed as mean ± SEM.  Statistical analysis was performed using 
SigmaStat software (Jandel Scientific Software, San Rafael, CA, USA).  Comparison between 
groups was made using one-way analysis of variance (ANOVA), followed by Student-Newman-
Keuls test.  A P value of less than 0.05 was considered significant. 
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3.3 RESULTS 
3.3.1 Induction of Wnt expression by TGF-β1 in podocytes 
We first performed a systematic analysis of the mRNA expression of all Wnt genes in cultured 
mouse podocytes after incubation with TGF-β1 by RT-PCR approach.  As shown in Figure 13A, 
a comprehensive survey of all 19 Wnts showed that the induction of mRNA expression of 
several Wnts, including Wnt1, Wnt2, Wnt9a, Wnt10b and Wnt11, was detected at different time 
points.  Slight inhibition of Wnt5b and Wnt16 was also observed, particularly at late time points.  
Notably, the expression of Wnt3a, Wnt4 and Wnt9b was undetectable in cultured podocytes 
throughout the experiments (data not shown).  Compared with other Wnts, the induction of Wnt1 
mRNA by TGF-β1 was most predominant.  Quantitative, real-time RT-PCR (qRT-PCR) results 
revealed that Wnt1 mRNA expression was induced by approximately 14-fold at 8 h after TGF-
β1 treatment in mouse podocytes (Figure 13B).  The induction of Wnt1 mRNA expression also 
occurred in a dose-dependent fashion; and TGF-β1 induced its mRNA level at the concentration 
as low as 0.5 ng/ml, which reached the peak at 2 ng/ml (Figure 13C). 
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Figure 13.  Expression of Wnt genes is induced by TGF-β1 in podocytes.  A, RT-PCR 
demonstrates an altered expression of various Wnts mRNA in cultured mouse podocytes after 
treatment with TGF-β1 at 2 ng/ml for various periods of time as indicated.  B and C, 
Quantitative real-time RT-PCR reveals that TGF-β1 induced Wnt1 mRNA expression in a time- 
and dosage- dependent manner.  Wnt1 mRNA levels were assessed by quantitative real-time RT-
PCR in mouse podocytes after treatment with a fixed amount of TGF-β1 (2 ng/ml) for various 
periods of time as indicated (B) or with various concentrations of TGF-β1 for 24 h (C).  Data are 
presented as mean ± SEM of three experiments.  *P < 0.05 versus control.  **P < 0.01 versus 
control.  
 
3.3.2 Activation of β-catenin in podocytes by TGF-β1  
To examine the biological consequence of Wnt induction in podocytes, we next investigated the 
activation of β-catenin, the principal downstream mediator of canonical Wnt signaling, in 
podocytes after TGF-β1 treatment.  As shown in Figure 14A, active, dephosphorylated form of 
β-catenin protein was induced in cultured mouse podocytes at 24 h after incubation with TGF-
β1, which sustained to 48 h.  This activation of β-catenin significantly lagged behind the Wnt1 
induction by TGF-β1.  The induction of active β-catenin protein was also dose-dependent; and 
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TGF-β1 induced active β-catenin at a concentration as low as 0.5 ng/ml, which reached the peak 
at 2 ng/ml (Figure 14B).  We further examined β-catenin activation and its subcellular 
distribution in podocytes after incubation with TGF-β1 for 24 h.  As illustrated in Figure 14C, β-
catenin predominantly displayed a plasma membrane-associated staining pattern in the resting, 
control podocytes (Figure 14C, arrowhead).  However, upon stimulation by TGF-β1, β-catenin 
underwent nuclear translocation, with disappearance of the plasma membrane-associated staining 
and concomitant emergence of nuclear β-catenin (Figure 14C, arrowheads).  This nuclear 
translocation of β-catenin, together with the Western blot results (Figure 14, A and B), clearly 
indicates the activation of canonical Wnt/β-ctaenin signaling in podocytes after TGF-β1 
treatment.  
3.3.3 DKK1 blocks Wnt/β-catenin signaling in podocytes 
To further corroborate the activation of Wnt/β-catenin signaling by TGF-β1, we sought to inhibit 
Wnt/β-catenin signaling by using DKK1, a secreted Wnt antagonist that specifically blocks the 
canonical pathway of Wnt signaling.  As shown in Figure 15A, transfection of podocytes with 
expression vector encoding constitutively active TGF-β1 (pCA-TGF-β1) induced β-catenin 
activation, as illustrated by an increased expression of active β-catenin.  However, co-
transfection with DKK1 expression vector (pFlag-DKK1) abolished β-catenin activation (Figure 
15A), suggesting that DKK1 is sufficient to antagonize the Wnt/β-catenin signaling activated by 
TGF-β1 in podocytes.    
We further investigated the potential downstream targets of TGF-β1/Wnt/β-catenin 
signaling that are relevant to podocyte dysfunction.  To this end, we examined the expression of 
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slit diaphragm protein nephrin and transcription factor Snail1.  As shown in Figure 15B, either 
incubation with TGF-β1 or transient transfection with Flag-tagged N-terminal truncated, 
stabilized β-catenin expression vector (pDel-β-cat) or HA-tagged Wnt1 expression vector (pHA-
Wnt1) was sufficient to suppress nephrin expression and concomitantly induced Snail1 
expression.   
We next tested whether blockade of Wnt/β-catenin signaling by DKK1 can attenuate 
TGF-β1-mediated podocyte dysfunction.  As shown in Figure 15, C and D, TGF-β1 suppressed 
nephrin expression in cultured mouse podocytes at different time points.  However, pre-
incubation with recombinant DKK1 protein was able to preserve nephrin expression in a dose-
dependent manner.  Taken together, it becomes clear that DKK1 is sufficient to impede Wnt/β-
catenin signaling and protect podocytes against TGF-β1-induced injury.  
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Figure 14.  β-catenin is activated by TGF-β1 in podocytes.  A and B, Western blot analyses 
demonstrate that TGF-β1 induced active β-catenin protein expression in a time- and dosage-
dependent manner.  Podocytes were treated with a fixed amount of TGF-β1 (2 ng/ml) for various 
periods of time as indicated (A) or with various concentrations of TGF-β1 for 48 h (B).  Total 
cell lysates were immunoblotted with specific antibodies against active β-catenin and α-tubulin, 
respectively.  C, Immunofluorescence staining demonstrates the activation of β-catenin and 
nuclear translocation in mouse podocytes after treatment with TGF-β1 at 2 ng/ml for 24 h.  
Arrowheads indicate β-catenin staining.  
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Figure 15.  Exogenous Wnt antagonist DKK1 blocks Wnt signaling induced by TGF-β1 in 
podocytes.  A, Western blot analysis demonstrates that exogenous DKK1 blocks the activation 
of β-catenin induced by TGF-β1.  Podocytes were transfected with constitutively active TGF-β1 
expression vector (pCA-TGF-β1), DKK1 expression vector (pFlag-DKK1) or empty vector 
pcDNA3, as indicated, for 48 h.  Total cell lysates were immunoblotted with specific antibodies 
against active β-catenin and α-tubulin, respectively.  B, TGF-β1/Wnt1/β-catenin cascade is 
sufficient for triggering nephrin suppression and Snail induction in podocytes.  Mouse podocytes 
were transiently transfected with expression vector pHA-Wnt1, pDel-β-cat or pcDNA, 
respectively, followed by incubation with TGF-β1 at 2 ng/ml for 48h.  Representative RT-PCR 
results demonstrated the mRNA expression of nephrin and Snail.  C and D, treatment of DKK1 
preserves nephrin mRNA expression repressed by TGF-β1.  Podocytes were pre-treated with 
recombinant protein DKK1 at 40 or 200 ng/ml for 1 h, followed with the treatment of TGF-β1 at 
2 ng/ml for 24 h or 48h.  Representative RT-PCR results (C) and quantitative data (D) 
demonstrate the mRNA expression of nephrin.  Data are presented as mean ± SEM of three 
experiments.  *P < 0.05 versus control.  †P<0.05 versus group treated with TGF-β1 alone. 
  
 
 80 
3.3.4  Ectopic TGF-β1 expression targets podocyte in vivo and induces proteinuria  
To assess the potential role of Wnt/β-catenin activation in podocyte dysfunction induced by 
TGF-β1, we sought to express bioactive, exogenous TGF-β1 in vivo by use of a hydrodynamic-
based gene delivery approach [224-225].  As shown in Figure 16A, several mammalian 
expression plasmid vectors were constructed, which contained the coding region of mouse wild 
type TGF-β1 full length cDNA (pWT-TGF-β1), C-terminus truncated TGF-β1 (pCT-TGF-β1) 
and constitutively active TGF-β1 (pCA-TGF-β1), respectively.  The pCA-TGF-β1 vector 
contained two cysteine to serine mutations at the positions 223 and 225 (C223S/C225S), which 
produces bioactive TGF-β1 that does not require acid activation [208], rendering it constitutively 
active.  To test the bioactivity of these TGF-β1 expression vectors, we examined their potential 
in inducing the expression of plasminogen activator inhibitor-1 (PAI-1), a sensitive TGF-β1 
target gene.  As shown in Figure 16B, little PAI-1 induction was observed in podocytes after 
transient transfection with either pWT-TGF-β1 or pCT-TGF-β1, compared with empty vector 
pcDNA3.  However, transfection with pCA-TGF-β1 dramatically induced PAI-1 expression, 
corroborating the bioactivity of this mutant, constitutively active TGF-β1 (Figure 16B).  
We next investigated the functional consequence of delivery of the expression plasmid 
encoding constitutively active TGF-β1 (pCA-TGF-β1) in vivo by single intravenous injection in 
mice.   As shown in Figure 16C, single administration of pCA-TGF-β1 plasmid markedly 
induced Smad3 phosphorylation, a surrogate marker for TGF-β receptor activation, in the 
glomerular lysates of the kidneys at 1 or 2 days after injection.  Double immunofluorescence 
staining for both phosphorylated Smad3 and nephrin revealed that podocytes in the glomeruli 
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were preferentially responsive to TGF-β1, with a positive staining for phosphorylated Smad3 
after TGF-β1 gene delivery (Figure 16D, arrowheads).   
Analysis of urine samples revealed that urinary albumin levels were substantially 
increased in mice that received TGF-β1 plasmid injection, compared to pcDNA3 controls 
(Figure 17A).  SDS-PAGE analysis demonstrated that albumin was the major constituent of 
urine proteins in these mice after ectopic expression of exogenous TGF-β1 (Figure 17B), 
suggesting defective glomerular filtration.  Consistently, exogenous TGF-β1 induced an altered 
nephrin distribution, from a linear staining along GBM to granular pattern, as illustrated by 
immunofluorescence staining, although it did not significantly affect nephrin abundance (Figure 
17C).  The expression of Wilms tumor 1 (WT1), an important transcription regulator that is 
exclusively expressed in podocytes in adult kidney, was significantly suppressed after exogenous 
TGF-β1 plasmid injection (Figure 17D).  Hence, single injection of the expression vector 
encoding constitutively active TGF-β1 is sufficient to cause podocyte injury and induce 
proteinuria in normal and healthy mice.   
3.3.5 Activation of Wnt/β-catenin signaling in vivo by TGF-β1 
We next examined the effects of TGF-β1 on Wnt/β-catenin signaling pathway in podocytes in 
vivo.  Quantitative real-time RT-PCR result revealed an increased expression of Wnt1 gene in 
glomeruli, which was detected at day 1 and sustained at day 2 after TGF-β1 plasmid injection 
(Figure 18A).  Subcellular fractionation of the isolated glomeruli, followed by Western blot 
analyses, indicated that β-catenin in both cytoplasmic and nuclear compartments was markedly 
induced after TGF-β1 gene delivery in vivo (Figure 18B).  Compared with pcDNA3 controls, 
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ectopic expression of TGF-β1 clearly promoted β-catenin to undergo nuclear translocation 
(Figure 18B), suggesting the activation of the canonical Wnt signaling.  We further studied the 
expression of several putative target genes of Wnt/β-catenin in the glomeruli after TGF-β1 gene 
delivery.  As shown in Figure 18, C through E, numerous well characterized Wnt/β-catenin 
target genes including Snail1, MMP-9, MMP-7, desmin and Fsp1 were upregulated in mouse 
glomeruli after ectopic expression of exogenous TGF-β1.   
 
Figure 16.  Ectopic expression of TGF-β1 targets glomerular podocytes in vivo.  A, diagram 
depicts the construction of wild type TGF-β1 (pWT-TGF-β1), C-terminus truncated TGF-β1 
(pCT-TGF-β1) and constitutively active TGF-β1 (pCA-TGF-β1) expression vectors.  B, 
Expression vector pCA-TGF-β1 dramatically induces PAI-1 gene expression in podocytes.  
Mouse podocyte were transiently transfected with expression vector pWT-TGF-β1, pCT-TGF-
β1 and pCA-TGF-β1 and pcDNA3 for 48 h, respectively.  Total cell lysates were immunoblotted 
with specific antibodies against PAI-1 and actin, respectively.  C and D, Delivery of 
constitutively active TGF-β1 gene induces Smad3 phosphorylation in glomerular podocytes in 
vivo.  One or two days after a single intravenous injection of either TGF-β1-expressing plasmid 
(pCA-TGF-β1) or empty vector (pcDNA3), glomerular lysates were prepared and 
immunoblotted with anti-phospho-Smad3 and anti-Smad1/2/3 antibodies.  Mouse kidney 
sections were immunostained with antibodies against phospho-specific Smad3 (red) and nephrin 
(green) (D).  Arrowheads indicate phospho-Smad3-positive podocytes.   
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Figure 17.  Ectopic expression of TGF-β1 causes proteinuria and podocyte dysfunction.  A, 
Urinary albumin levels in mice after ectopic expression of exogenous TGF-β1.  Male BALB/c 
mice were injected intravenously with TGF-β1-expression plasmid (pCA-TGF-β1) or empty 
vector (pcDNA3).  Urinary albumin was determined at 1 or 2 days after injection, and expressed 
as mg per mg creatinine.  **P < 0.01 versus pcDNA3 control (n = 6).  B, Representative SDS-
PAGE shows the urinary proteins at day 1 and day 2 after pCA-TGF-β1 plasmid injection.  C, 
Immunofluorescence staining shows the expression and distribution pattern of nephrin in 
different groups as indicated.  Arrowheads indicate a dot-like pattern of nephrin after TGF-β1 
plasmid injection.  D, Western blot analysis demonstrates the suppression of WT1 by TGF-β1 in 
vivo.  Whole glomerular lysates were immunoblotted with anti-WT1 and α-tubulin, respectively.   
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Figure 18.  Ectopic expression TGF-β1 activates Wnt/β-catenin signaling and induces its 
downstream target gene expression in vivo.  A, Quantitative real-time RT-PCR reveals that 
TGF-β1 induced Wnt1 mRNA expression in mouse glomeruli.  B, TGF-β1 induces cytoplasmic 
β-catenin accumulation and its nuclear translocation in mouse glomeruli.  Glomeruli were 
isolated from mouse kidneys at 1 day after injection of TGF-β1 expression plasmid (pCA-TGF-
β1) or empty vector (pcDNA3).  Nuclear and cytoplasmic proteins from the isolated glomeruli 
were prepared and immunoblotted with antibodies against β-catenin, histone H3 (H3) or 
GAPDH, respectively.  The ratios of β-catenin per control proteins (histone H3 for nuclear 
protein and GAPDH for cytoplasmic protein) are shown.  C through G, Quantitative real-time 
RT-PCR reveals that TGF-β1 induces the mRNA expression of Wnt/β-catenin downstream 
genes such as Snail1, MMP-9, MMP-7, desmin and Fsp-1.  Various mRNA levels were assessed 
by quantitative real-time RT-PCR in the isolated glomeruli in different groups as indicated.  Data 
are presented as mean ± SEM of three glomerular preparations, each of them contains a pool of 
two animals.  *P < 0.05 versus control group.  **P < 0.01 versus control group.   
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3.3.6 Ectopic expression of DKK1 gene blocks Wnt/β-catenin signaling and reduces 
proteinuria  
To further investigate the role of Wnt/β-catenin signaling in mediating TGF-β1-induced 
podocyte injury and proteinuria, we sought to block Wnt signaling in vivo by its natural 
antagonist DKK1.  To this end, mice were injected concurrently with TGF-β1 expression vector 
(pCA-TGF-β1) in the presence or absence of DKK1 expression vector (pFlag-DKK1).  As 
shown in Figure 19A, ectopic expression of constitutively active TGF-β1 induced both active 
and total β-catenin expression in the glomeruli, as demonstrated by Western blot analyses of 
glomerular lysates.  However, concomitant expression of DKK1 gene evidently abolished β-
catenin induction and activation.  Immunohistochemical staining produced similar results.  As 
shown in Figure 19B, renal β-catenin protein was increased in glomerular podocytes and tubular 
cells after ectopic expression of exogenous TGF-β1 (Figure 19B, arrowheads).  The positive β-
catenin staining localized in the cytoplasmic and nuclear compartments was significantly 
diminished when DKK1 gene was concurrently administrated.  Interestingly, delivery of DKK1 
gene significantly mitigated albuminuria induced by exogenous TGF-β1 (Figure 19C), indicating 
an important role for Wnt/β-catenin signaling in mediating TGF-β1-induced podocyte injury and 
proteinuria.   
We next examined the expression of Wnt/β-catenin downstream target genes in the 
glomeruli of these mice.  As shown in Figure 20, A through D, administration of DKK1 gene 
resulted in significant inhibition of the Wnt/β-catenin targets genes.  Quantitative RT-PCR 
revealed that DKK1 significantly inhibited the mRNA expression of Snail1, MMP-9, MMP-7 
and LEF-1 genes, which were induced in mouse glomeruli after TGF-β1 expression (Figure 20).  
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Notably, albeit not statistically significant, DKK1 seemed also to block the induction of PAI-1 
expression by TGF-β1 (Figure 20E).   
 
Figure 19.  Ectopic expression of DKK1 blocks β-catenin activation and reduces 
albuminuria induced by TGF-β1 in vivo.  A, Western blot analyses demonstrate that DKK1 
blocks the TGF-β1-induced active and total β-catenin expression in mouse glomeruli.  Whole 
glomerular lysates were immunoblotted with anti-active β-catenin, β-catenin and α-tubulin 
antibodies, respectively, at day 2 after intravenous plasmid injection.  B, Representative 
micrographs demonstrate β-catenin expression and localization in different groups at day 2.  
Mouse kidney sections were immunostained with antibody against β-catenin.  Arrowheads 
indicate β-catenin-positive podocytes.  C, Urinary albumin levels in different group as indicated.  
Data are presented as mean ± SEM of six animals.  *P < 0.05; **P < 0.01.   
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Figure 20.  Exogenous DKK1 blocks Wnt/β-catenin target gene expression induced by 
TGF-β1 in vivo.  Quantitative real-time RT-PCR reveals that exogenous DKK1 inhibits TGF-
β1-induced the mRNA expression of Wnt/β-catenin target genes, including Snail1 (A), MMP-9 
(B), MMP-7 (C), LEF-1 (D), and PAI-1 (E).  Various mRNA levels were assessed in the isolated 
glomeruli from mice injected with different expression vectors as indicated at day2.  Data are 
presented as mean ± SEM of three glomerular preparations, each of them contains a pool of two 
animals.  *P < 0.05; **P < 0.01 (n = 3).   
 
3.4 DISCUSSION 
The results presented here clearly illustrate a critical role for Wnt/β-catenin signaling in 
meditating the pathogenesis of podocyte injury and proteinuria in vivo after ectopic expression of 
fibrogenic TGF-β1.  We demonstrate that Wnt1 is upregulated and β-catenin is activated in the 
glomeruli after exogenous TGF-β1 expression through a hydrodynamic-based gene delivery 
approach, which leads to the over-expression of several key Wnt target genes including Snail1, 
resulting in podocyte injury and onset of proteinuria.  Moreover, Wnt antagonist DKK1 is 
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effective in blocking TGF-β1-mediated β-catenin activation in vivo and in vitro, leading to 
significant inhibition of Wnt target genes and mitigation of albuminuria in mice.  These studies 
establish a simple mouse model in which ectopic expression of TGF-β1, per se, is sufficient to 
cause podocyte injury in vivo and results in proteinuric kidney disease.  Our data also underscore 
that targeting Wnt/β-catenin could be a promising novel therapeutic strategy for the treatment of 
a variety of proteinuric kidney disease in humans. 
TGF-β1, as a fibrogenic factor, is up-regulated in the injured kidneys in experimental 
animal models and in humans of virtually every type of chronic kidney diseases [226].  Although 
exaggerated TGF-β signaling is considered to be a major profibrotic stimulus in mesangial injury 
and expansion, little is known about its pathobiology in podocytes in vivo.  Earlier studies on 
transgenic mice over-expressing TGF-β1 under albumin promoter (Alb/TGF-β1 mice) have 
pointed toward a causative role of TGF-β1 in the pathogenesis of nephropathies, as these mice 
spontaneously develop proteinuria, progressive glomerulosclerosis and interstitial fibrosis, with 
advanced kidney failure leading to approximately 50% animal death at 5-12 weeks of age [129].  
However, because of the tremendous heterogeneity in renal pathology, these mice have not been 
widely used as an animal model of chronic kidney diseases.  In this study, by a single injection of 
naked plasmid vector encoding constitutively active TGF-β1, we have established a simple, 
quick, reproducible and accessible mouse model of podocyte injury and proteinuria (Figure 17).  
As TGF-β1 is the sole culprit of kidney injury in this model, these mice could also serve as an in 
vivo model to dissect the cellular and molecular mechanism of TGF-β1 action in the kidneys.  
Interestingly, of three major cell types in the glomeruli, podocytes seem to be the most 
susceptible cells that are readily responsive to TGF-β1 stimulation in vivo, as illustrated by 
Smad3 phosphorylation, a surrogate marker for TGF-β receptor activation (Figure 16).  Such an 
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activation of TGF-β1 evidently leads to induction of numerous Wnt genes in podocytes, 
particularly Wnt1 (Figure 13), which results in the stabilization and accumulation of β-catenin, 
as well as its nuclear translocation.  In addition, TGF-β1 and Wnt ligands may work in concert to 
regulate gene expression [227], as previous studies suggest that β-catenin can form a complex 
with Smad4 [228].  In short, TGF-β1 is categorically linked to the activation of Wnt/β-catenin, a 
developmental signaling that is recently implicated in podocyte injury and proteinuria [201].   
Wnt/β-catenin signaling is highly conserved during the evolution and plays important 
role in controlling many biologic processes during the embryogenesis and tumorigenesis.  At the 
cellular level, this signaling regulates morphology, proliferation, motility and cell fate.  
Inappropriate activation of this signaling has been linked to tumorigenesis in humans [229].  At 
least two Wnt ligands, Wnt9b and Wnt4, are intimately involved in the epithelial differentiation 
of metanephric mesenchymal progenitors during nephron formation [230], whereas their 
signaling is considered to be silent in adult kidney.  Depending on different receptors and cellular 
context, Wnt proteins can activate three intracellular signaling pathways, including the canonical 
β-catenin-dependent pathway, the non-canonical, β-catenin-independent planar cell polarity 
(PCP) pathway and Wnt/Ca2+ pathway [179].  However, it appears that the signaling elicited by 
Wnts in podocytes after TGF-β1 expression in this study is mediated by the canonical pathway.  
It is worthwhile to point out that aberrant expression of Wnts and activation of β-catenin are 
common findings in a wide variety of kidney diseases in animal models and in humans, 
including unilateral ureteral obstruction (UUO), adriamycin nephropathy, ischemia-reperfusion 
induced acute kidney injury and diabetic nephropathy [193, 201, 231-232]. 
How activation of Wnt/β-catenin signaling causes podocyte injury remains elusive, but it 
could be related to its ability to regulate epithelial-mesenchymal transition (EMT), a cell 
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phenotypic alteration process taking place in embryonic development, cancer metastasis and 
tissue fibrosis [233-235].  Earlier studies demonstrate that podocytes also undergo EMT in vitro 
after TGF-β1 stimulation, and this process could be a potential pathway leading to podocyte 
dysfunction and proteinuria under pathological conditions [42].  In agreement with this notion, 
EMT has been reported as a potential explanation for podocyte dysfunction, detachment and 
depletion in human diabetic nephropathy.  It is of interest to point out that Snail1, a key 
transcription factor controlling EMT [128, 236], is a downstream target gene of Wnt/β-catenin 
signaling [235].  Snail1, in turn, could directly suppress nephrin expression in podocytes [202] 
and induces the expression of other mesenchymal markers.  Indeed, either incubation with TGF-
β1 or over-expression of Wnt1 or stabilized β-catenin by transient transfection is sufficient to 
induce Snail1 expression and suppress nephrin expression in podocytes (Figure 15).  In vivo 
TGF-β1/Wnt/β-catenin cascade also induces glomerular expression of Snail1 as well as 
mesenchymal marker Fsp1 (Figure 18).  Taken together, by inducing Snail1 expression, Wnt/β-
catenin signaling suppresses podocyte-specific protein nephrin and promotes podocyte 
dedifferentiation and mesenchymal transition, leading to the onset of proteinuria. 
Besides Snail1, numerous downstream target genes of Wnt/β-catenin are identified to be 
activated in the glomeruli upon TGF-β1 expression, such as MMP-9, MMP-7, LEF-1, Fsp1 and 
PAI-1.  Among these genes, induction of LEF-1, a DNA-binding transcription regulator that 
interacts with β-catenin by forming a trans-activation protein complex [237], clearly favors a 
positive feedback loop that re-enforces Wnt signaling.   Matrix metalloproteinases (MMPs) are a 
family of extracellular proteases that are responsible for the degradation of the extracellular 
matrix and other substrates during tissue remodeling [238-239].  Although the exact action of 
MMPs in podocyte injury is unclear, MMP-mediated extracellular domain shedding of nephrin 
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could play a role.  PAI-1, a well characterized fibrogenic factor, is another direct downstream 
target of Wnt/β-catenin signaling, and its induction may also contribute to the development of 
nephropathy in mice after TGF-β1 expression.  It is conceivable that each of these target genes 
activated by Wnt/β-catenin could promote podocyte injury and proteinuria in their own ways.  
However, it is interesting to note that many of these genes including Snail1, MMPs, Fsp1 and 
PAI-1 share the same action by promoting cell migration.  An increased podocyte migration 
could render them from stationary to motile state, which could reduce their adhesions to GBM 
and promote detachment.  This view is in line with previous observation that EMT leads to an 
increased podocyte detachment and depletion in diabetic nephropathy.   
Our present study also indicates that targeting Wnt/β-catenin signaling might be an 
effective strategy to mitigate podocyte injury and proteinuria.  DKK1, a secreted Wnt antagonist, 
specifically binds to the Wnt co-receptors LRP-5/6, leading to blockade of the canonical Wnt 
pathway [194].  Because delivery of exogenous DKK1 gene via intravenous injection is 
sufficient to lead to substantial expression of DKK1 in kidney as previously reported [193], it is 
not unexpected that DKK1 gene therapy blocks β-catenin activation, suppresses Wnt/β-catenin 
target gene expression and mitigates albuminuria.  Therefore, these studies underscore a pivotal 
role of the canonical Wnt/β-catenin signaling in mediating TGF-β1-triggered podocyte injury 
and proteinuria in vivo.   
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4.0  GENERAL DISCUSSION AND FUTURE DIRECTIONS 
In the first project, we demonstrated the induction of PINCH1 by fibrogenic factor TGF-β1 in 
glomerular podocytes.  We then revealed the nuclear-cytoplasmic shuttling of PINCH1, which is 
dependent on its putative NES/NLS motif.  More importantly, we have identified WT1 as a 
novel binding partner of PINCH1 in podocytes and showed that such binding of PINCH1/WT1 
affects the podocyte-specific podocalyxin gene expression.  In summary, we established that 
PINCH1, adaptor protein that localizes at the focal adhesions and is important for mediating 
integrin signaling, is acting as a novel, nuclear transcription regulator that interacts with WT1 to 
affect gene expression in podocytes.   
In the second project, we investigated the role of Wnt/β-catenin signaling in podocyte 
injury induced by TGF-β1.  We showed that among all 19 Wnt genes, Wnt1 expression was 
dramatically induced by TGF-β1 in cultured podocytes.  We further demonstrated that Wnt 
canonical pathway was activated by TGF-β1 and Wnt antagonist DKK1 was able to block such 
activation in vitro.  By intravenous injection of naked plasmid encoding constitutively active 
TGF-β1, we established a simple mouse model of podocyte injury and proteinuria.  Using this 
model, we showed that TGF-β1 activated Wnt/β-catenin signaling and induced its downstream 
target genes in vivo.  Furthermore, we showed that DKK1 gene therapy effectively blocked 
Wnt/β-catenin signaling, inhibited the expression of Wnt target genes, and mitigated proteinuria 
in vivo.   
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Taken together, we have identified and delineated two important but separate signaling 
pathways downstream of TGF-β1, which lead to podocytes injury and proteinuria.  As shown in 
Figure 21, on one hand, TGF-β1 induces PINCH1 expression and its nuclear translocation, 
wherein it interacts with transcriptional factor WT1 and blocks the WT1-mediated gene 
expression, leading to podocyte dysfunction.  On the other hand, TGF-β1 is able to trigger 
podocyte injury via canonical Wnt/β-catenin signaling.  At this stage, the relative contribution of 
PINCH1/WT1 and Wnt/β-catenin pathways to podocyte injury remains unknown.  However, it is 
highly likely that both pathways are necessary and indispensable for mediating TGF-β1-induced 
podocyte dysfunction and proteinuria.  This notion is corroborated by the observation that Wnt 
antagonist DKK1 only partially blocks TGF-β1-induced proteinuria, indicating that 
PINCH1/WT1 or other signaling besides Wnt/β-catenin plays a role in this pathogenic process.  
Whether Wnt/β-catenin and PINCH1/WT1 signaling can cross-talk with each other remains a 
fascinating question awaiting further investigation.   
4.1 GENERAL DISCUSSION 
4.1.1 Conditionally immortalized podocyte cell lines 
Podocytes are terminally differentiated glomerular epithelial cells, which play a critical role in 
maintaining the filtration barrier with complex structure of foot processes.  The development of 
immortalized podocytes cell lines is a major impetus to the study of podocytes in vitro.  In our 
study, we used both human and mouse podocytes cell lines which were derived with the use of 
 94 
conditional immortalization techniques with a temperature-sensitive transgene [203, 240].  These 
cells can proliferate at the “permissive” temperature (33°C) and enter growth arrest and start to 
differentiate after transferring to the “nonpermissive” temperature (37°C).  Although they 
express multiple markers of differentiated podocytes, including nephrin, podocin, CD2AP and 
synaptopodin, after differentiation [203, 240], there is no evidence for imitating the sophisticated 
three-dimensional structure of foot processes and the slit diaphragm in the monolayer culture of 
podocytes in vitro.  Despite these pitfalls, here we used these cell lines to investigate the 
subcellular pathways, gene transcription and the effects of established and novel therapeutic 
agents in podocytes.  To validate the in vitro results, we have developed and adopted TGF-β1 
mouse model for investigating the functional effects of different intracellular signaling and 
mediators in podocytes in vivo. 
 
Figure 21.  Diagram of two signaling pathways under TGF-β1 stimulation leading to 
podocyte dysfunction and proteinuria. 
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4.1.2 TGF-β1 mouse model 
Although hyperactive TGF-β signaling is observed in the injured kidneys in experimental animal 
models and in humans of virtually every type of chronic kidney diseases [226], little is known 
about its pathobiology in podocytes in vivo.  Earlier studies on transgenic Alb/TGF-β1 mice 
revealed the causative role of TGF-β1 in the pathogenesis of nephropathies, as these mice 
spontaneously developed proteinuria, progressive glomerulosclerosis and interstitial fibrosis, 
with advanced kidney failure leading to approximately 50% animal death at 5-12 weeks of age 
[129, 241].  In addition, these studies demonstrated that progressive depletion of podocytes was 
associated with a robust increase in podocyte apoptosis from transgenic animals and indicated 
that podocyte depletion may be an initial lesion in the development of chronic kidney disease 
[130].  However, previous studies in our lab have suggested that the EMT process of podocytes, 
rather than their loss, is the primary cause of podocyte dysfunction leading to proteinuria in 
many common glomerular diseases [42].  We speculated that podocytes respond to injurious 
stimuli in different ways, depending on the severity and duration of the injury.  In our studies, we 
used a simple, quick, reproducible and accessible mouse model to investigate podocyte injury 
induced by TGF-β1.  Because it was much easier to regulate the expression level of TGF-β1 by 
controlling the concentration of naked plasmid vector compared to TGF-β1 transgenic mice, we 
were able to observe the cellular and molecular changes in podocytes before the presence of 
apoptosis.  Importantly, among the three major cell types in the glomeruli, podocytes are the 
most susceptible target in vivo as illustrated by Smad3 phosphorylation, a surrogate marker for 
TGF-β receptor activation (Figure 16).  Therefore we propose that the TGF-β1 mouse model 
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established in this study is a valuable model to investigate the role of TGF-β1 and its 
downstream signaling in podocytes injury. 
4.1.3 Potential drawbacks  
In the first part of my studies, in vitro results demonstrated that PINCH1 undergoes nuclear 
translocation, interacts with WT1 and blocks WT1-regulated gene expression in cultured 
podocytes.  Although nuclear translocation of PINCH1 and increased interaction between 
PINCH1 and WT1 have been shown in TGF-β1 mouse model, the direct biological 
consequences of these new findings in vivo remains to be explored.  Due to the limitation of our 
mouse model, we cannot draw the conclusion that the interaction of PINCH1/WT1 directly 
causes podocyte dysfunction and proteinuria; however, the prediction that PINCH1 plays a role 
in regulating WT1-dependent podocytes differentiation can be made based on in vitro data.  
Consistent with this notion, another LIM domain containing protein, Wilms tumor 1 interacting 
protein (WTIP), has been reported to undergo nuclear translocation and interact with WT1 in 
podocytes, although there is also no direct evidence for WTIP-dependent repression of WT1 
transcriptional activity in vivo [220, 242].  This raises a general theme that focal adhesion-
associated proteins such as PINCH1 and WTIP are able to translocate into the nucleus and 
participate in gene regulation.  In future, genetic approaches can be use in this study.  Transgenic 
mouse overexpressing PINCH1 or its mutant version with disrupted nuclear localization in a 
podocyte-specific fashion will be an elegant and valuable approach to investigate the direct 
function of PINCH1 as transcription regulator in vivo. 
As shown in Figure 8, we identified a putative NES/NLS region at the C-terminus of 
PINCH1, which is required for mediating cytoplasmic-nuclear shuttling of PINCH1 under both 
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basal and TGF-β1 stimulated conditions.  Deletion of this region or mutations of leucine to 
alanine in this region impairs PINCH1 nuclear translocation, which was demonstrated by 
Western blot analysis of the nuclear and cytoplasmic fractions.  Since leucine as a hydrophobic 
residue often acts as a core residue to stabilize protein structure, we cannot rule out the 
possibility that the failure of nuclear translocation of mutant and truncated PINCH1 is due to the 
overall structural perturbation.  Mutating surrounding residues such as lysine may provide a 
negative control, however there is still the possibility that mutation of leucine may affect the 
whole structure of PINCH1.  Another way to demonstrate the importance of a putative NES/NLS 
is to fuse the NES/NLS sequence to a heterologous protein, such as GFP, and then show that the 
putative NES/NLS drives the nuclear import of the heterologous protein by imaging studies.  
Using a similar approach, fusion of the mutant NES/NLS sequence to a heterologous protein 
should block its nuclear import. 
In the second part of my studies, we investigated the role for Wnt/β-catenin signaling in 
meditating the pathogenesis of podocyte injury and proteinuria in vivo after ectopic expression of 
fibrogenic TGF-β1.  Multiple signaling pathways can be activated by TGF-β1 stimulation, 
including Smad-dependent and Smad-independent signaling; and transcription levels of hundreds 
of genes are expected to change either positively or negatively.  The activation of Wnt/β-catenin 
induced by TGF-β1 may be one of several signal pathways which are responsible for the onset of 
proteinuria and podocyte dysfunction.  Gene therapy with DKK1 only partially mitigates 
albuminuria, which can be explained by two different reasons: TGF-β1 induces podocyte 
dysfunction and proteinuria by activating other signaling pathways independent of Wnt/β-
catening signaling; or β-catenin is activated by other upstream proteins besides Wnt proteins.  It 
should be noted that although we cannot exclude the possibility of the involvement of other 
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pathways leading to podocyte dysfunction in this mouse model, the critical role of Wnt/β-catenin 
signaling in mediating podocyte injury has been confirmed in β-catenin knockout mice.  Earlier 
studies in our lab have demonstrated that Wnt/β-catenin is activated in the podocytes of mouse 
and human kidneys with primary glomerular disorders; that ectopic expression of Wnt1 gene in 
mice exacerbates podocyte injury and albuminuria; and that mice with podocyte-specific ablation 
of β-catenin are protected against the development of albuminuria after adriamycin injury [201]. 
4.1.4 Therapeutic implication and future directions 
My studies and recent reports from our lab suggest a critical role of Wnt/β-catenin signal 
pathway in podocyte dysfunction and renal fibrosis [193, 201].  The results of gene therapy with 
DKK1 suggest that targeting Wnt/β-catenin signaling might be an effective strategy to hinder the 
progression of podocyte injury and renal interstitial fibrosis.  As a Wnt antagonist, DKK1 
specifically blocks Wnt ligands binding to LRP5/6, the co-receptors that are obligatory for 
transmitting the canonical pathway of Wnt/β-catenin signaling [187].  Blocking Wnt/β-catenin 
singaling leads to the reduction of β-catenin accumulation, suppression of Wnt/β-catenin target 
genes, attenuation of proteinuria and podocyte injury, and reduction of renal matrix deposition 
and fibrosis.  This conclusion is in line with a previous report that secreted frizzled-related 
protein 4 (sFRP4) blocks β-catenin signaling in tubular epithelial cells and suppressed the 
progression of renal fibrosis in UUO model [243].  In addition, recent studies from our lab 
indicate that administration of the vitamin D analog (paricalcitol) also suppresses of β-catenin–
mediated gene transcription through inducing a physical interaction between the vitamin D 
receptor and β-catenin in podocytes, and leads to amelioration of established proteinuria [244].  
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Therefore, it appears that targeting canonical Wnt/β-catenin signaling could be a novel strategy 
for therapeutic intervention of a variety of proteinuric and fibrotic kidney diseases.  
Two independent pathways associated with podocyte dysfunction under TGF-β1 
stimulation have been revealed by this study.  Although both of them are shown to play 
important and distinct roles in regulating gene expression and podocytes biological functions, 
further studies are needed to fully understand their relative contributions as well as their 
pathogenic mechanisms in vivo.  Toward this end, transgenic mouse model with overexpression 
of wild-type and mutant PINCH1 in a podocyte-specific fashion can be utilized to investigate the 
biological consequences induced by PINCH1 nuclear translocation and its interaction with WT1 
in vivo.  The mechanism of podocyte dysfunction caused by nuclear translocation can be 
examined by studies on WT1 targeted gene expressions and cytoskeleton changes related to 
PINCH1 translocation.  Furthermore, the mechanism of PINCH1 nuclear translocation needs to 
be determined.  The nuclear translocation of WTIP has been shown to require JNK activity to 
assemble a multiprotein complex of the scaffolding protein JNK-interacting protein 3 and the 
motor dynein [245].  The proteins involved in promoting PINCH1 shuttling are still unknown.  
In addition, further studies are warranted to investigate the potential interaction between 
PINCH1 and ILK after nuclear translocation.  A previous report has shown that TGF-β1 inhibits 
the formation of IPP complex in podocytes [159], despite that the expressions of both ILK and 
PINCH1 are upregulated in that setting.  As ILK is also found in the nucleus in some reports, 
whether nuclear ILK can interact with PINCH1 (or/and WT1) in podocytes remains to be 
explored [246].  Finally, the exact mechanism how β-catenin activation leads to podocyte 
dysfunction remains elusive.  Key target genes which lead to the change of slit diaphragm, foot 
processes effacement and proteinuria can be identified and functionally validated in vivo by 
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“knock in” and “knock out” approaches.  Inhibitors for β-catenin activity can be used to 
demonstrate the direct biological function of active β-catenin in podocytes dysfunction, and 
exploited as novel therapeutic agents for treatment of proteinuric and fibrotic kidney diseases.   
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